

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

**EP 0 745 676 A1**

(12)

**EUROPEAN PATENT APPLICATION**

(43) Date of publication:  
04.12.1996 Bulletin 1996/49

(51) Int Cl.<sup>6</sup>: **C12N 15/54, C12N 9/12,  
C12Q 1/68**

(21) Application number: **96303880.7**

(22) Date of filing: **30.05.1996**

(84) Designated Contracting States:  
**AT BE CH DE ES FI FR GB IT LI NL SE**

(30) Priority: **31.05.1995 US 455686**

(71) Applicant: **Amersham Life Science Inc**  
**Cleveland, Ohio 44128 (US)**

(72) Inventors:  
• **Davis, Maria**  
**Twinsburg, Ohio (US)**

• **Fuller, Carl**  
**Cleveland Heights, Ohio 44118 (US)**  
• **Moffett, Bruce**  
**Shaker Heights, Ohio 44122 (US)**

(74) Representative: **Rollins, Anthony John**  
**Group Patents,**  
**Amersham International plc,**  
**White Lion Road**  
**Amersham, Bucks HP7 9LL (GB)**

(54) **Thermostable DNA polymerases**

(57) An enzymatically active DNA polymerase having between 540 and 582 amino acids having a tyrosine at a position equivalent to position 667 of Taq DNA polymerase, wherein said polymerase lacks 5' to 3' exonuclease activity, and wherein said polymerase has at

least 95% homology in its amino acid sequence to the DNA polymerase of Thermus aquaticus, Thermus flavus or Thermus thermophilus, and wherein said polymerase forms a single polypeptide band on an SDS PAGE.

**EP 0 745 676 A1**

**Description**Background of the Invention

5 The present invention relates to novel thermostable DNA polymerases, the genes and vectors encoding them and their use in DNA sequencing.

US Patents 4,889,818 and 5,079,352 describe the isolation and expression of a DNA polymerase known as Taq DNA Polymerase (hereinafter referred to as Taq). It is reported that amino-terminal deletions wherein approximately one-third of the coding sequence is absent have resulted in producing a gene product that is quite active in polymerase assays. Taq is described as being of use in PCR (polymerase chain reaction).

10 US Patent No. 5,075,216 describes the use of Taq in DNA sequencing.

International patent application WO 92/06/06188 describes a DNA polymerase having an identical amino acid sequence to Taq except that it lacks the N-terminal 235 amino acids of Taq and its use in sequencing. This DNA polymerase is known as  $\Delta$  Taq.

15 US Patent 4,795,699 describes the use of T7 type DNA polymerases (T7) in DNA sequencing. These are of great use in DNA sequencing in that they incorporate dideoxy nucleoside triphosphates (NTPs) with an efficiency comparable to the incorporation of deoxy NTPs; other polymerases incorporate dideoxy NTPs far less efficiently which requires comparatively large quantities of these to be present in sequencing reactions.

At the DOE Contractor-Grantee Workshop (Nov. 13-17, 1994, Santa Fe) and the I. Robert Lehman Symposium (Nov 11-14, 1994, Sonoma), Prof. S. Tabor identified a site in DNA polymerases that can be modified to incorporate dideoxy NTPs more efficiently. He reported that the presence or absence of a single hydroxy group (tyrosine vs. phenylalanine) at a highly conserved position on *E. coli*, DNA Polymerase I, T7, and Taq makes more than a 1000-fold difference in their ability to discriminate against dideoxy NTPs. (See also European Patent Application 94203433.1 published May 31, 1995, Publication No. 0 655 506 A1 and hereby incorporated by reference herein.)

Summary of the Invention

25 The present invention provides a DNA polymerase having an amino acid sequence differentiated from Taq in that it lacks the N-terminal 272 amino acids and has the phenylalanine at position 667 (of native Taq) replaced by tyrosine. Preferably, the DNA polymerase has methionine at position 1 (equivalent to position 272 of Taq) (hereinafter referred to as FY2). The full DNA sequence is given as Fig 1 (SEQ. ID. NO. 1). Included within the scope of the present invention are DNA polymerases having substantially identical amino acid sequences to the above which retain thermostability and efficient incorporation of dideoxy NTPs.

30 By a substantially identical amino acid sequence is meant a sequence which contains 540 to 582 amino acids that may have conservative amino acid changes compared with Taq which do not significantly influence thermostability or nucleotide incorporation, i.e. other than the phenylalanine to tyrosine conversion. Such changes include substitution of like charged amino acids for one another, or amino acids with small side chains for other small side chains, e.g., ala for val. More drastic changes may be introduced at noncritical regions where little or no effect on polymerase activity is observed by such a change.

40 The invention also features DNA polymerases that lack between 251 and 293 (preferably 271 or 272) of the N-terminal amino acids of *Thermus flavus* (Tfl) and have the phenylalanine at position 666 (of native Tfl) replaced by tyrosine; and those that lack between 253 and 295 (preferably 274) of the N-terminal amino acids of *Thermus thermophilus* (Tth) and have the phenylalanine at position 669 (of native Tth) replaced by tyrosine.

45 By efficient incorporation of dideoxy NTPs is meant the ability of a polymerase to show little, if any, discrimination in the incorporation of ddNTPs when compared with dNTPs. Suitably efficient discrimination is less than 1:10 and preferably less than 1:5. Such discrimination can be measured by procedures known in the art.

50 One preferred substantially identical amino acid sequence to that given above is that which contains 562 amino acids having methionine at position 1 and alanine at position 2 (corresponding to positions 271 and 272 of native Taq) (hereinafter referred to as FY3). A full DNA sequence is given as Fig. 2. This is a preferred DNA polymerase for expression by a gene of the present invention.

The purified DNA polymerases FY2 and FY3 both give a single polypeptide band on SDS polyacrylamide gels, unlike  $\Delta$  Taq, having either a phenylalanine or tyrosine at position 667 which forms several polypeptide bands of similar size on SDS polyacrylamide gels.

55 A second preferred substantially identical amino acid sequence is that which lacks 274 of the N-terminal amino acids of *Thermus thermophilus* having methionine at position 1, and the phenylalanine to tyrosine mutation at position 396 (corresponding to position 669 of native Tth) (hereinafter referred to as FY4). A full DNA sequence is given as Fig. 5 (SEQ. ID. NO. 14).

The present invention also provides a gene encoding a DNA polymerase of the present invention. In order to assist

in the expression of the DNA polymerase activity, the modified gene preferably codes for a methionine residue at position 1 of the new DNA polymerase. In addition, in one preferred embodiment of the invention, the modified gene also codes for an alanine at position 2 (corresponding to position 272 of native Taq).

In a further aspect, the present invention provides a vector containing the gene encoding the DNA polymerase activity of the present invention, e.g., encoding an amino acid sequence differentiated from native Taq in that it lacks the N-terminal 272 amino acids and has phenylalanine at position 396 (equivalent to position 667 of Taq) replaced by tyrosine or a substantially identical amino acid sequence thereto.

In a yet further aspect, the present invention provides a host cell comprising a vector containing the gene encoding the DNA polymerase activity of the present invention, e.g., encoding an amino acid sequence differentiated from native Taq in that it lacks the N-terminal 272 amino acids and has phenylalanine at position 396 (equivalent to position 667 of native Taq) replaced by tyrosine or a substantially identical amino acid sequence thereto.

The DNA polymerases of the present invention are preferably in a purified form. By purified form is meant that the DNA polymerase is isolated from a majority of host cell proteins normally associated with it; preferably the polymerase is at least 10% (w/w) of the protein of a preparation, even more preferably it is provided as a homogeneous preparation, e.g., a homogeneous solution. Preferably the DNA polymerase is a single polypeptide on an SDS polyacrylamide gel.

The DNA polymerases of the present invention are suitably used in sequencing, preferably in combination with a pyrophosphatase. Accordingly, the present invention provides a composition which comprises a DNA polymerase of the present invention in combination with a pyrophosphatase, preferably a thermostable pyrophosphatase such as *Thermoplasma acidophilum* pyrophosphatase. (Schafer, G. and Richter, O.H. (1992) *Eur. J. Biochem.* 209, 351-355).

The DNA polymerases of the present invention can be constructed using standard techniques. By way of example, mutagenic PCR primers can be designed to incorporate the desired Phe to Tyr amino acid change (FY mutation) in one primer. In our hands these primers also carried restriction sites that are found internally in the sequence of the Taq polymerase gene clone of Delta Taq, pWB253, which was used by us as template DNA. However, the same PCR product can be generated with this primer pair from any clone of Taq or with genomic DNA isolated directly from *Thermus aquaticus*. The PCR product encoding only part of the gene is then digested with the appropriate restriction enzymes and used as a replacement sequence for the clone of Delta Taq digested with the same restriction enzymes. In our hands the resulting plasmid was designated pWB253Y. The presence of the mutation can be verified by DNA sequencing of the amplified region of the gene.

Further primers can be prepared that encode for a methionine residue at the N-terminus that is not found at the corresponding position of Taq, the sequence continuing with amino acid residue 273. These primers can be used with a suitable plasmid, e.g., pWB253Y DNA, as a template for amplification and the amplified gene inserted into a vector, e.g., pRE2, to create a gene, e.g., pRE273Y, encoding the polymerase (FY2). The entire gene can be verified by DNA sequencing.

Improved expression of the DNA polymerases of the present invention in the pRE2 expression vector was obtained by creating further genes, pREFY2pref (encoding a protein identical to FY2) and pREFY3 encoding FY3. A mutagenic PCR primer was used to introduce silent codon changes (i.e., the amino acid encoded is not changed) at the amino terminus of the protein which did not affect the sequence of the polypeptide. These changes led to increased production of FY2 polymerase. FY3 was designed to promote increased translation efficiency *in vivo*. In addition to the silent codon changes introduced in pREFY2pref, a GCT codon was added in the second position (SEQ. ID. NO. 2), as occurs frequently in strongly expressed genes in *E. coli*. This adds an amino acid to the sequence of FY2, and hence the protein was given its own designation FY3. Both constructs produce more enzyme than pRE273Y.

Silent codon changes such as the following increase protein production in *E. coli*:

substitution of the codon GAG for GAA;

substitution of the codon AGG, AGA, CGG or CGA for CGT or CGC;

substitution of the codon CTT, CTC, CTA, TTG or TTA for CTG; substitution of the codon ATA for ATT or ATC;

substitution of the codon GGG or GGA for GGT or GGC.

The present invention also provides a method for determining the nucleotide base sequence of a DNA molecule. The method includes providing a DNA molecule annealed with a primer molecule able to hybridize to the DNA molecule; and incubating the annealed molecules in a vessel containing at least one deoxynucleotide triphosphate, and a DNA polymerase of the present invention. Also provided is at least one DNA synthesis terminating agent which terminates DNA synthesis at a specific nucleotide base. The method further includes separating the DNA products of the incubating reaction according to size, whereby at least a part of the nucleotide base sequence of the DNA molecule can be determined.

In preferred embodiments, the sequencing is performed at a temperature above 50°C, 60°C, or 70°C.

In other preferred embodiments, the DNA polymerase has less than 1000, 250, 100, 50, 10 or even 2 units of exonuclease activity per mg of polymerase (measured by standard procedure, see below) and is able to utilize primers having only 4, 6 or 10 bases; and the concentration of all four deoxynucleoside triphosphates at the start of the incubating step is sufficient to allow DNA synthesis to continue until terminated by the agent, e.g., a ddNTP.

For cycle sequencing, the DNA polymerases of the present invention make it possible to use significantly lower amounts of dideoxynucleotides compared to naturally occurring enzymes. That is, the method involves providing an excess amount of deoxynucleotides to all four dideoxynucleotides in a cycle sequencing reaction, and performing the cycle sequencing reaction.

5 Preferably, more than 2, 5, 10 or even 100 fold excess of a dNTP is provided to the corresponding ddNTP.

In a related aspect, the invention features a kit or solution for DNA sequencing including a DNA polymerase of the present invention and a reagent necessary for the sequencing such as dITP, deaza GTP, a chain terminating agent such as a ddNTP, and a manganese-containing solution or powder and optionally a pyrophosphatase.

10 In another aspect, the invention features a method for providing a DNA polymerase of the present invention by providing a nucleic acid sequence encoding the modified DNA polymerase, expressing the nucleic acid within a host cell, and purifying the DNA polymerase from the host cell.

In another related aspect, the invention features a method for sequencing a strand of DNA essentially as described above with one or more (preferably 2, 3 or 4) deoxyribonucleoside triphosphates, a DNA polymerase of the present invention, and a first chain terminating agent. The DNA polymerase causes the primer to be elongated to form a first series of first DNA products differing in the length of the elongated primer, each first DNA product having a chain terminating agent at its elongated end, and the number of molecules of each first DNA products being approximately the same for substantially all DNA products differing in length by no more than 20 bases. The method also features providing a second chain terminating agent in the hybridized mixture at a concentration different from the first chain terminating agent, wherein the DNA polymerase causes production of a second series of second DNA products differing in the length of the elongated primer, with each second DNA product having the second chain terminating agent at its elongated end. The number of molecules of each second DNA product is approximately the same for substantially all second DNA products differing in length from each other by from 1 to 20 bases, and is distinctly different from the number of molecules of all the first DNA products having a length differing by no more than 20 bases from that of said second DNA products.

25 In preferred embodiments, three or four such chain terminating agents can be used to make different products and the sequence reaction is provided with a magnesium ion, or even a manganese or iron ion (e.g., at a concentration between 0.05 and 100 mM, preferably between 1 and 10 mM); and the DNA products are separated according to molecular weight in four or less lanes of a gel.

30 In another related aspect, the invention features a method for sequencing a nucleic acid by combining an oligonucleotide primer, a nucleic acid to be sequenced, between one and four deoxyribonucleoside triphosphates, a DNA polymerase of the present invention, and at least two chain terminating agents in different amounts, under conditions favoring extension of the oligonucleotide primer to form nucleic acid fragments complementary to the nucleic acid to be sequenced. For example, the chain terminating agent may be a dideoxynucleotide terminator for adenine, guanine, cytosine or thymine. The method further includes separating the nucleic acid fragments by size and determining the nucleic acid sequence. The agents are differentiated from each other by intensity of a label in the primer extension products.

40 While it is common to use gel electrophoresis to separate DNA products of a DNA sequencing reaction, those in the art will recognize that other methods may also be used. Thus, it is possible to detect each of the different fragments using procedures such as time of flight mass spectrometry, electron microscopy, and single molecule detection methods.

45 The invention also features an automated DNA sequencing apparatus having a reactor including reagents which provide at least two series of DNA products formed from a single primer and a DNA strand. Each DNA product of a series differs in molecular weight and has a chain terminating agent at one end. The reagents include a DNA polymerase of the present invention. The apparatus includes a separating means for separating the DNA product along one axis of the separator to form a series of bands. It also includes a band reading means for determining the position and intensity of each band after separation along the axis, and a computing means that determines the DNA sequence of the DNA strand solely from the position and intensity of the bands along the axis and not from the wavelength of emission of light from any label that may be present in the separating means.

50 Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims.

#### Description of the Preferred Embodiments

55 The drawings will first briefly be described.

#### Drawings

Figs 1-4 are the DNA sequences, and corresponding amino acid sequences, of FY2, FY3, and the DNA polymer-

ases of *T. flavus* and *Thermus thermophilus*, respectively. Figure 5 is the DNA sequence and corresponding amino acid sequence of FY4.

### Examples

The following examples serve to illustrate the DNA polymerases of the present invention and their use in sequencing.

### Preparation of FY DNA Polymerases (FY2 and FY3)

#### Bacterial Strains

*E. coli* strains: MV1190 [ $\Delta$ (*srl* - *recA*) 306::Tn10,  $\Delta$  (*lac-proAB*), *thi*, *supE*, *F'* (*traD36 proAB<sup>+</sup> lac<sup>R</sup> lacZ*  $\Delta$ M15)]; DH $\lambda$ <sup>+</sup> [*gyrA96*, *recA1*, *relA1*, *endA1*, *thi-1*, *hsdR17*, *supE44*,  $\lambda$ <sup>+</sup>]; M5248 [ $\lambda$ (*bio275*, *cl857*, *cllI*<sup>+</sup>, *N*<sup>+</sup>,  $\Delta$  (*H1*))].

#### PCR

Reaction conditions based on the procedure of Barnes (91 *Proc. Nat'l. Acad. Sci.* 2216-2220, 1994) were as follows: 20mM Tricine pH8.8, 85mM KOAc, 200mM dNTPs, 10% glycerol, 5% DMSO, 0.5mM each primer, 1.5mM MgOAc, 2.5 U HotTub (Amersham Life Science Inc.), 0.025 U DeepVent (New England Biolabs), 1-100 ng target DNA per 100ml reaction. Cycling conditions were 94°C 30s, 68°C 10m40s for 8 cycles; then 94°C 30s, 68°C 12m00s for 8 cycles; then 94°C 30s, 68°C 13m20s for 8 cycles; then 94°C 30s, 68°C 14m40s for 8 cycles.

#### *In vitro* mutagenesis

Restriction enzyme digestions, plasmid preparations, and other *in vitro* manipulations of DNA were performed using standard protocols (Sambrook et al., Molecular Cloning 2nd Ed. Cold Spring Harbor Press, 1989). PCR (see protocol above) was used to introduce a Phe to Tyr amino acid change at codon 667 of native Taq DNA polymerase (which is codon 396 of FY2). Oligonucleotide primer 1 dGCTTGGGCAGAGGATCCGCCGGG (SEQ. ID. NO. 3) spans nucleotides 954 to 976 of the coding region of SEQ. ID. NO. 1 including a BamHI restriction site. Mutagenic oligo primer 2 dGGGATGGCTAGCTCCTGGGAGAGGCGGTGGGCCGACATGCCGTAGA GGACCCCGTAGTTGATGG (SEQ. ID. NO. 4) spans nucleotides 1178 to 1241 including an NheI site and codon 396 of Sequence ID. NO. 1. A clone of exo-Taq deleted for the first 235 amino acids, pWB253 encoding DeltaTaq polymerase (Barnes, 112 *Gene* 29-35, 1992) was used as template DNA. Any clone of Taq polymerase or genomic DNA from *Thermus aquaticus* could also be utilized to amplify the identical PCR product. The PCR product was digested with BamHI and NheI, and this fragment was ligated to BamHI/NheI digested pWB253 plasmid to replace the corresponding fragment to create pWB253Y, encoding polymerase FY1. Cells of *E. coli* strain MV1190 were used for transformation and induction of protein expression, although any host strain carrying a *lac* repressor could be substituted. DNA sequencing verified the Phe to Tyr change in the coding region.

PCR primer 3 dGGAATTCATATGGACGATCTGAAGCTCTCC (SEQ. ID. NO. 5) spanning the start codon and containing restriction enzyme sites, was used with PCR primer 4 dGGGGTACCAAGCTTCACTCCTTGGCGGAGAG (SEQ. ID. NO. 6) containing restriction sites and spanning the stop codon (codon 562 of Sequence ID. NO. 1). A methionine start codon and restriction enzyme recognition sequences were added to PCR primer 5 dGGAATTCAT-ATGCTGGAGAGGCTTGAGTTT (SEQ. ID. NO. 7), which was used with primer 4 above. PCR was performed using the above primer pairs, and plasmid pWB253Y as template. The PCR products were digested with restriction enzymes NdeI and KpnI and ligated to NdeI/KpnI digested vector pRE2 (Reddi et al., 17 *Nucleic Acids Research* 10,473-10,488, 1989) to make plasmids pRE236Y, encoding FY1 polymerase, and pRE273Y encoding FY2 polymerase, respectively. Cells of *E. coli* strain DH $\lambda$ <sup>+</sup> were used for primary transformation with this and all subsequent pRE2 constructions, and strain M5248 ( $\lambda$ cl857) was used for protein expression, although any comparable pair of *E. coli* strains carrying the *cl*<sup>+</sup> and *cl857* alleles could be utilized. Alternatively, any *rec<sup>+</sup> cl<sup>+</sup>* strain could be induced by chemical agents such as nalidixic acid to produce the polymerase. The sequences of both genes were verified. pRE273Y was found to produce a single polypeptide band on SDS polyacrylamide gels, unlike pRE253Y or pRE236Y.

Primer 6 dGGAATTCATATGCTGGAACGTCTGGAGTTTGGCAGCCTC CTC (SEQ. ID. NO. 8) and primer 4 were used to make a PCR product introducing silent changes in codon usage of FY2. The product was digested with NdeI/BamHI and ligated to a pRE2 construct containing the 3' end of FY2 to create pREFY2pref, encoding FY2 DNA polymerase. Primer 7 dGGAATTCATATGGCTCTGGAACGTCTGGAGTTTGGCAGCCTCCTC (SEQ. ID. NO. 9) and primer 4 were used to make a PCR product introducing an additional alanine codon commonly occurring at the second position of highly expressed genes. The NdeI/BamHI digested fragment was used as above to create pREFY3, encoding FY3

DNA polymerase.

#### Preparation of FY4 DNA Polymerase

#### 5 Bacterial Strains

*E. coli* strains: DH1 $\lambda^+$  [*gyrA96*, *recA1*, *relA1*, *endA1*, *thi-1*, *hsdR17*, *supE44*,  $\lambda^+$ ]; M5248 [ $\lambda$  (*bio275*, *cl857*, *cllI+*, *N+*,  $\Delta$  (*H1*))].

#### 10 PCR

Genomic DNA was prepared by standard techniques from *Thermus thermophilus*. The DNA polymerase gene of *Thermus thermophilus* is known to reside on a 3 kilobase AlwNI fragment. To enrich for polymerase sequences in some PCR reactions, the genomic DNA was digested prior to PCR with AlwNI, and fragments of approximately 3 kb were selected by agarose gel electrophoresis to be used as template DNA. Reaction conditions were as follows: 10mM Tris pH8.3, 50mM KCl, 800 $\mu$ M dNTPs, 0.001% gelatin, 1.0 $\mu$ M each primer, 1.5mM MgCl<sub>2</sub>, 2.5 U Tth, 0.025 U Deepvent (New England Biolabs), per 100 $\mu$ l reaction. Cycling conditions were 94°C 2 min, then 35 cycles of 94°C 30s, 55°C 30s, 72°C 3 min, followed by 72 °C for 7 min.

#### 20 *In vitro* mutagenesis

Restriction enzyme digestions, plasmid preparations, and other *in vitro* manipulations of DNA were performed using standard protocols (Sambrook et al., 1989). Plasmid pMR1 was constructed to encode an exonuclease-free polymerase, with optimized codons for expression in *E. coli* at the 5' end. Primer 8 (SEQ. ID. NO. 10) (GGAATTCAT-ATGCTGGAACGTCTGGAATTCGGCAGCCTC) was used with Primer 9 (SEQ. ID. NO.11) (GGGGTACCCTAACCCTT-GGCGGAAAGCCAGTC) to create a PCR product from *Tth* genomic DNA, which was digested with restriction enzymes NdeI and KpnI and inserted into plasmid pRE2 (Reddi et al., 1989, Nucleic Acids Research 17, 10473 - 10488) digested with the same enzymes.

To create the desired F396Y mutation, two PCR products were made from *Tth* chromosomal DNA. Primer 8 above was used in combination with Primer 10 (SEQ. ID. NO. 12) (GGGATGGCTAGCTCCTGGGAGAGCCTAT-GGGCGGACAT GCCGTAGAGGACGCCGTAGTTCACCG) to create a portion of the gene containing the F to Y amino acid change as well as a silent change to create an NheI restriction site. Primer 11 (SEQ. ID. NO. 13) (CTAGCTAGCCATCCCCTA CGAAGAAGCGGTGGCCT) was used in combination with primer 9 above to create a portion of the gene from the introduced NheI site to the stop codon at the 3' end of the coding sequence. The PCR product of Primers 8 and 10 was digested with NdeI and NheI, and the PCR product of Primers 9 and 11 was digested with NheI and KpnI. These were introduced into expression vector pRE2 which was digested with NdeI and KpnI to produce plasmid pMR5. In addition to the desired changes, pMR5 was found to have a spurious change introduced by PCR, which led to an amino acid substitution, K234R. Plasmid pMR8 was created to eliminate this substitution, by replacing the AflII/BamHI fragment of pMR5 for the corresponding fragment from pMR1. The FY4 polymerase encoded by plasmid pMR8 (SEQ. ID. NO. 14) is given in Figure 5.

Cells of *E. coli* strain DH1 $\lambda^+$  were used for primary transformation, and strain M5248 ( $\lambda$ cl857) was used for protein expression, although any comparable pair of *E. coli* strains carrying the *cl+* and *cl857* alleles could be utilized. Alternatively, any *rec+* *cl+* strain could be induced by chemical agents such as nalidixic acid to produce the polymerase.

#### 45 Protein Sequencing

Determinations of amino terminal protein sequences were performed at the W.M. Keck Foundation, Biotechnology Resource Laboratory, New Haven, Connecticut.

#### 50 Purification of Polymerases

A 1 liter culture of 2X LB (2% Bacto-Tryptone, 1% Bacto-Yeast Extract, 0.5% NaCl) + 0.2% Casamino Acids + 20 mM KPO<sub>4</sub> pH 7.5 + 50  $\mu$ g/ml Ampicillin was inoculated with a glycerol stock of the appropriate cell strain and grown at 30°C with agitation until cells were in log phase (0.7-1.0 OD<sub>590</sub>). 9 liters of 2X LB + 0.2% Casamino Acids + 20 mM KPO<sub>4</sub> pH 7.5 + 0.05% Mazu Anti-foam was inoculated with 1 liter of log phase cells in 10 liter Microferm Fermentors (New Brunswick Scientific Co.). Cells were grown at 30°C under 15 psi pressure, 350-450 rpm agitation, and an air flow rate of 14,000 cc/min  $\pm$  1000 cc/min. When the OD<sub>590</sub> reached 1.5-2.0, the cultures were induced by increasing the temperature to 40-42°C for 90-120 minutes. The cultures were then cooled to < 20°C and the cells harvested by

centrifugation in a Sorvall RC-3B centrifuge at 5000 rpm at 4°C for 15-20 minutes. Harvested cells were stored at -80°C.

Frozen cells were broken into small pieces and resuspended in pre-warmed (90-95°C) Lysis Buffer (20 mM Tris pH 8.5, 1 mM EDTA, 10 mM MgCl<sub>2</sub>, 16 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 0.1% Tween 20, 0.1% Nonidet P-40, 1 mM PMSF). Resuspended cells were then heated rapidly to 80°C and incubated at 80°C for 20 minutes with constant stirring. The suspension was then rapidly cooled on ice. The cell debris was removed by centrifugation using a Sorvall GSA rotor at 10,000 rpm for 20 minutes at 4°C. The NaCl concentration of the supernatant was adjusted to 300 mM. The sample was then passed through a diethylaminoethyl cellulose (Whatman DE-52) column that had been previously equilibrated with Buffer A (20 mM Tris pH 8.5, 1 mM EDTA, 0.1% Tween 20, 0.1% Nonidet P-40, 300 mM NaCl, 10% glycerol, 1 mM DTT), and polymerase collected in the flow through. The sample was then diluted to a concentration of NaCl of 100mM and applied to a Heparin-sepharose column. The polymerase was eluted from the column with a NaCl gradient (100-500 mM NaCl). The sample was then dialyzed against Buffer B (20 mM Tris pH 8.5, 1 mM EDTA, 0.1% Tween 20, 0.1% Nonidet P-40, 10 mM KCl, 10% glycerol, 1 mM DTT) and further diluted as needed to lower the conductivity of the sample to the conductivity of Buffer B. The sample was then applied to a diethylaminoethyl (Waters DEAE 15 HR) column and eluted with a 10-500 mM KCl gradient. The polymerase was then diluted with an equal volume of Final Buffer (20 mM Tris pH 8.5, 0.1 mM EDTA, 0.5% Tween 20, 0.5% Nonidet P-40, 100 mM KCl, 50% glycerol, 1 mM DTT) and dialyzed against Final Buffer.

#### Assay of Exonuclease Activity

The exonuclease assay was performed by incubating 5 µl (25-150 units) of DNA polymerase with 5 µg of labelled [<sup>3</sup>H]-pBR322 PCR fragment (1.6x10<sup>4</sup> cpm/µg DNA) in 100 µl of reaction buffer of 20 mM Tris-HCl pH 8.5, 5 mM MgCl<sub>2</sub>, 10 mM KCl, for 1 hour at 60 °C. After this time interval, 200 µl of 1:1 ratio of 50 µg/ml salmon sperm DNA with 2 mM EDTA and 20% TCA with 2% sodium pyrophosphate were added into the assay aliquots. The aliquots were put on ice for 10 min and then centrifuged at 12,000g for 10 min. Acid-soluble radioactivity in 200 µl of the supernatant was quantitated by liquid scintillation counting. One unit of exonuclease activity was defined as the amount of enzyme that catalyzed the acid solubilization of 10 nmol of total nucleotide in 30 min at 60 °C.

#### Utility in DNA Sequencing

##### Example 1: DNA Sequencing with FY Polymerases (e.g., FY2 and FY3)

The following components were added to a microcentrifuge vial (0.5 ml) : 0.4 pmol M13 DNA (e.g., M13mp18, 1.0 µg); 2 µl Reaction Buffer ( 260 mM Tris-HCl, pH 9.5 65 mM MgCl<sub>2</sub>); 2 µl of labeling nucleotide mixture (1.5 µM each of dGTP, dCTP and dTTP); 0.5 µl (5 µCi) of [α-<sup>33</sup>P]dATP (about 2000Ci/mmol); 1 µl -40 primer (0.5 µM; 0.5 pmol/µl 5'GTTTTCCAGTCACGAC-3'); 2 µl of a mixture containing 4 U/µl FY polymerase and 6.6 U/ml *Thermoplasma acidophilum* inorganic pyrophosphatase (32 U/µl polymerase and 53 U/ml pyrophosphatase in 20 mM Tris (pH8.5), 100 mM KCl, 0.1 mM EDTA, 1 mM DTT, 0.5% NP-40, 0.5% TWEEN-20 and 50% glycerol, diluted 8 fold in dilution buffer (10 mM Tris-HCl pH8.0, 1 mM 2-mercaptoethanol, 0.5% TWEEN-20, 0.5% NP-40)); and water to a total volume of 17.5 µl. These components (the labeling reaction) were mixed and the vial was placed in a constant-temperature water bath at 45°C for 5 minutes.

Four vials were labeled A, C, G, and T, and filled with 4 µl of the corresponding termination mix: ddA termination mix (150 µM each dATP, dCTP, dGTP, dTTP, 1.5 µM ddATP); ddT termination mix (150 µM each dATP, dCTP, dGTP, dTTP, 1.5 µM ddTTP); ddC termination mix (150 µM each dATP, dCTP, dGTP, dTTP, 1.5 µM ddCTP); ddG termination mix (150 µM each dATP, dCTP, dGTP, dTTP, 1.5 µM ddGTP).

The labeling reaction was divided equally among the four termination vials (4 µl to each termination reaction vial), and tightly capped.

The four vials were placed in a constant-temperature water bath at 72°C for 5 minutes. Then 4 µl of Stop Solution (95% Formamide 20 mM EDTA, 0.05% Bromophenol Blue, 0.05% Xylene Cyanol FF) added to each vial, and heated briefly to 70°-80°C immediately prior to loading on a sequencing gel (8% acrylamide, 8.3 M urea). Autoradiograms required an 18-36 hour exposure using Kodak XAR-5 film or Amersham Hyperfilm MP. High-quality sequence results with uniform band intensities were obtained. The band intensities were much more uniform than those obtained with similar protocols using *Taq* DNA polymerase or  $\Delta$  *Taq* DNA polymerase.

##### Example 2: DNA Cycle Sequencing with FY Polymerases

The following components were added to a microcentrifuge vial (0.5 ml) which is suitable for insertion into a thermocycler machine (e.g., Perkin-Elmer DNA Thermal Cycler): 0.05 pmol or more M13 DNA (e.g., M13mp18, 0.1 µg) , or 0.1 µg double-stranded plasmid DNA (e.g., pUC19); 2 µl Reaction Buffer ( 260 mM Tris-HCl, pH 9.5 65 mM

MgCl<sub>2</sub>); 1 µl 3.0 µM dGTP; 1 µl 3.0 µM dTTP; 0.5 µl (5 µCi) of [α-<sup>33</sup>P]dATP (about 2000 Ci/mmol); 1 µl -40 primer (0.5 µM; 0.5 pmol/µl 5'GTTTCCCAGTCACGAC-3'); 2 µl of a mixture containing 4 U/µl FY polymerase and 6.6 U/ml *Thermoplasma acidophilum* inorganic pyrophosphatase (32 U/µl polymerase and 53 U/ml pyrophosphatase in 20 mM Tris (pH8.5), 100 mM KCl, 0.1 mM EDTA, 1 mM DTT, 0.5% NP-40, 0.5% TWEEN-20 and 50% glycerol, diluted 8 fold in dilution buffer (10 mM Tris-HCl pH8.0, 1 mM 2-mercaptoethanol, 0.5% TWEEN-20, 0.5% NP-40)); and water to a total volume of 17.5 µl.

These components (labeling reaction mixture) were mixed and overlaid with 10 µl light mineral oil (Amersham). The vial was placed in the thermocycler and 30-100 cycles (more than 60 cycles is unnecessary) from 45°C for 1 minute to 95°C for 0.5 minute performed. (Temperatures can be cycled from 55°-95°C, if desired). The temperatures may be adjusted if the melting temperature of the primer/template is significantly higher or lower, but these temperatures work well for most primer-templates combinations. This step can be completed in about 3 minutes per cycle.

Four vials were labeled A, C, G, and T, and filled with 4 ml of the corresponding termination mix: ddA termination mix (150 µM each dATP, dCTP, dGTP, dTTP, 1.5 µM ddATP); ddT termination mix (150 µM each dATP, dCTP, dGTP, dTTP, 1.5 µM ddTTP); ddC termination mix (150 µM each dATP, dCTP, dGTP, dTTP, 1.5 µM ddCTP); ddG termination mix (150 µM each dATP, dCTP, dGTP, dTTP, 1.5 µM ddGTP). No additional enzyme is added to the termination vials. The enzyme carried in from the prior (labeling) step is sufficient.

The cycled labeling reaction mixture was divided equally among the four termination vials (4 µl to each termination reaction vial), and overlaid with 10 µl of light mineral oil.

The four vials were placed in the thermocycler and 30-200 cycles (more than 60 cycles is unnecessary) performed from 95°C for 15 seconds, 55°C for 30 seconds, and 72°C for 120 seconds. This step was conveniently completed overnight. Other times and temperatures are also effective.

Six µl of reaction mixture was removed (avoiding oil), 3 µl of Stop Solution (95% Formamide 20 mM EDTA, 0.05% Bromophenol Blue, 0.05% Xylene Cyanol FF) added, and heated briefly to 70°-80°C immediately prior to loading on a sequencing gel. Autoradiograms required an 18-36 hour exposure using Kodak XAR-5 film or Amersham Hyperfilm MP. High-quality sequence results with uniform band intensities were obtained. The band intensities were much more uniform than those obtained with similar protocols using *Taq* DNA polymerase or  $\Delta$  *Taq* DNA polymerase.

#### Example 3: Sequencing with dGTP analogs to eliminate compression artifacts.

For either of the sequencing methods outlined in examples 1 and 2, 7-Deaza-2'-deoxy-GTP can be substituted for dGTP in the labeling and termination mixtures at exactly the same concentration as dGTP. When this substitution is made, secondary structures on the gels are greatly reduced. Similarly, 2'-deoxyinosinetriphosphate can also be substituted for dGTP but its concentration must be 10-fold higher than the corresponding concentration of dGTP. Substitution of dTTP for dGTP is even more effective in eliminating compression artifacts than 7-deaza-dGTP.

#### Example 4: Other Sequencing methods using FY polymerases

FY polymerases have been adapted for use with many other sequencing methods, including the use of fluorescent primers and fluorescent-dideoxy-terminators for sequencing with the ABI 373A DNA sequencing instrument.

#### Example 5: SDS-Polyacrylamide Gel Electrophoresis

Protein samples were run on a 14 X 16 mm 7.5 or 10% polyacrylamide gel. (Gels were predominantly 10% Polyacrylamide using a 14 X 16 mm Hoefer apparatus. Other sizes, apparatuses, and percentage gels are acceptable. Similar results can also be obtained using the Pharmacia Phast Gel system with SDS, 8-25% gradient gels. Reagent grade and ultrapure grade reagents were used.) The stacking gel consisted of 4% acrylamide (30:0.8, acrylamide: bisacrylamide), 125 mM Tris-HCl pH 6.8, 0.1% Sodium Dodecyl Sulfate (SDS). The resolving gel consisted of 7.5 or 10% acrylamide (30:0.8, acrylamide: bisacrylamide), 375 mM Tris-HCl pH 8.8, 0.1% SDS. Running Buffer consisted of 25 mM Tris, 192 mM Glycine and 0.1% SDS. 1X Sample Buffer consisted of 25 mM Tris-HCl pH 6.8, 0.25% SDS, 10% Glycerol, 0.1M Dithiothreitol, 0.1% Bromophenol Blue, and 1mM EDTA. A 1/4 volume of 5X Sample Buffer was added to each sample. Samples were heated in sample buffer to 90-100°C for approximately 5 minutes prior to loading. A 1.5 mm thick gel was run at 50-100 mA constant current for 1-3 hours (until bromophenol blue was close to the bottom of the gel). The gel was stained with 0.025% Coomassie Blue R250 in 50% methanol, 10% acetic acid and destained in 5% methanol, 7% acetic acid solution. A record of the gel was made by taking a photograph of the gel, by drying the gel between cellulose film sheets, or by drying the gel onto filter paper under a vacuum.

Other embodiments are within the following claims.



## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

(i) APPLICANT: AMERSHAM LIFE SCIENCE

(ii) TITLE OF INVENTION: THERMOSTABLE DNA  
POLYMERASES

(iii) NUMBER OF SEQUENCES: 14

## (iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Lyon & Lyon  
(B) STREET: 633 West Fifth Street  
Suite 4700  
(C) CITY: Los Angeles  
(D) STATE: California  
(E) COUNTRY: U.S.A.  
(F) ZIP: 90071-2066

## (v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
storage  
(B) COMPUTER: IBM Compatible  
(C) OPERATING SYSTEM: IBM P.C. DOS 5.0  
(D) SOFTWARE: Word Perfect 5.1

## (vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: To Be Assigned  
(B) FILING DATE:  
(C) CLASSIFICATION:

## (vii) PRIOR APPLICATION DATA:

Prior applications total,  
including application  
described below: one

(A) APPLICATION NUMBER: US 08/455,686  
(B) FILING DATE: May 31, 1995

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Warburg, Richard J.  
(B) REGISTRATION NUMBER: 32,327  
(C) REFERENCE/DOCKET NUMBER: 219/304-PCT

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (213) 489-1600  
(B) TELEFAX: (213) 955-0440  
(C) TELEX: 67-3510

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1686 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ix) FEATURE:

(A) NAME/KEY: FY2  
(B) LOCATION: 1...1683

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

ATG CTG GAG AGG CTT GAG TTT GGC AGC CTC CTC CAC GAG TTC GGC CTT	48
Met Leu Glu Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly Leu	
1 5 10 15	
CTG GAA AGC CCC AAG GCC CTG GAG GAG GCC CCC TGG CCC CCG CCG GAA	96
Leu Glu Ser Pro Lys Ala Leu Glu Glu Ala Pro Trp Pro Pro Glu	
20 25 30	
GGG GCC TTC GTG GGC TTT GTG CTT TCC CGC AAG GAG CCC ATG TGG GCC	144

EP 0 745 676 A1

	Gly	Ala	Phe	Val	Gly	Phe	Val	Leu	Ser	Arg	Lys	Glu	Pro	Met	Trp	Ala	
			35					40					45				
5	GAT	CTT	CTG	GCC	CTG	GCC	GCC	GCC	AGG	GGG	GGC	CGG	GTC	CAC	CGG	GCC	192
	Asp	Leu	Leu	Ala	Leu	Ala	Ala	Ala	Arg	Gly	Gly	Arg	Val	His	Arg	Ala	
		50					55					60					
10	CCC	GAG	CCT	TAT	AAA	GCC	CTC	AGG	GAC	CTG	AAG	GAG	GCG	CGG	GGG	CTT	240
	Pro	Glu	Pro	Tyr	Lys	Ala	Leu	Arg	Asp	Leu	Lys	Glu	Ala	Arg	Gly	Leu	
		65				70					75					80	
15	CTC	GCC	AAA	GAC	CTG	AGC	GTT	CTG	GCC	CTG	AGG	GAA	GGC	CTT	GGC	CTC	288
	Leu	Ala	Lys	Asp	Leu	Ser	Val	Leu	Ala	Leu	Arg	Glu	Gly	Leu	Gly	Leu	
					85					90					95		
20	CCG	CCC	GGC	GAC	GAC	CCC	ATG	CTC	CTC	GCC	TAC	CTC	CTG	GAC	CCT	TCC	336
	Pro	Pro	Gly	Asp	Asp	Pro	Met	Leu	Leu	Ala	Tyr	Leu	Leu	Asp	Pro	Ser	
				100						105				110			
25	AAC	ACC	ACC	CCC	GAG	GGG	GTG	GCC	CGG	CGC	TAC	GGC	GGG	GAG	TGG	ACG	384
	Asn	Thr	Thr	Pro	Glu	Gly	Val	Ala	Arg	Arg	Tyr	Gly	Gly	Glu	Trp	Thr	
				115				120					125				
30	GAG	GAG	GCG	GGG	GAG	CGG	GCC	GCC	CTT	TCC	GAG	AGG	CTC	TTC	GCC	AAC	432
	Glu	Glu	Ala	Gly	Glu	Arg	Ala	Ala	Leu	Ser	Glu	Arg	Leu	Phe	Ala	Asn	
			130				135					140					
35	CTG	TGG	GGG	AGG	CTT	GAG	GGG	GAG	GAG	AGG	CTC	CTT	TGG	CTT	TAC	CGG	480
	Leu	Trp	Gly	Arg	Leu	Glu	Gly	Glu	Glu	Arg	Leu	Leu	Trp	Leu	Tyr	Arg	
		145				150				155						160	
40	GAG	GTG	GAG	AGG	CCC	CTT	TCC	GCT	GTC	CTG	GCC	CAC	ATG	GAG	GCC	ACG	528
	Glu	Val	Glu	Arg	Pro	Leu	Ser	Ala	Val	Leu	Ala	His	Met	Glu	Ala	Thr	
					165					170					175		
45	GGG	GTG	CGC	CTG	GAC	GTG	GCC	TAT	CTC	AGG	GCC	TTG	TCC	CTG	GAG	GTG	576
	Gly	Val	Arg	Leu	Asp	Val	Ala	Tyr	Leu	Arg	Ala	Leu	Ser	Leu	Glu	Val	
				180					185					190			
50	GCC	GAG	GAG	ATC	GCC	CGC	CTC	GAG	GCC	GAG	GTC	TTC	CGC	CTG	GCC	GGC	624
	Ala	Glu	Glu	Ile	Ala	Arg	Leu	Glu	Ala	Glu	Val	Phe	Arg	Leu	Ala	Gly	
			195				200					205					
55	CAC	CCC	TTC	AAC	CTC	AAC	TCC	CGG	GAC	CAG	CTG	GAA	AGG	GTC	CTC	TTT	672
	His	Pro	Phe	Asn	Leu	Asn	Ser	Arg	Asp	Gln	Leu	Glu	Arg	Val	Leu	Phe	
		210					215					220					
60	GAC	GAG	CTA	GGG	CTT	CCC	GCC	ATC	GGC	AAG	ACG	GAG	AAG	ACC	GGC	AAG	720
	Asp	Glu	Leu	Gly	Leu	Pro	Ala	Ile	Gly	Lys	Thr	Glu	Lys	Thr	Gly	Lys	
		225				230				235						240	

EP 0 745 676 A1

	CGC TCC ACC AGC GCC GCC GTC CTG GAG GCC CTC CGC GAG GCC CAC CCC	768
	Arg Ser Thr Ser Ala Ala Val Leu Glu Ala Leu Arg Glu Ala His Pro	
	245 250 255	
5	ATC GTG GAG AAG ATC CTG CAG TAC CGG GAG CTC ACC AAG CTG AAG AGC	816
	Ile Val Glu Lys Ile Leu Gln Tyr Arg Glu Leu Thr Lys Leu Lys Ser	
	260 265 270	
10	ACC TAC ATT GAC CCC TTG CCG GAC CTC ATC CAC CCC AGG ACG GGC CGC	864
	Thr Tyr Ile Asp Pro Leu Pro Asp Leu Ile His Pro Arg Thr Gly Arg	
	275 280 285	
15	CTC CAC ACC CGC TTC AAC CAG ACG GCC ACG GCC ACG GGC AGG CTA AGT	912
	Leu His Thr Arg Phe Asn Gln Thr Ala Thr Ala Thr Gly Arg Leu Ser	
	290 295 300	
20	AGC TCC GAT CCC AAC CTC CAG AAC ATC CCC GTC CGC ACC CCG CTT GGG	960
	Ser Ser Asp Pro Asn Leu Gln Asn Ile Pro Val Arg Thr Pro Leu Gly	
	305 310 315 320	
25	CAG AGG ATC CGC CGG GCC TTC ATC GCC GAG GAG GGG TGG CTA TTG GTG	1008
	Gln Arg Ile Arg Arg Ala Phe Ile Ala Glu Glu Gly Trp Leu Leu Val	
	325 330 335	
30	GCC CTG GAC TAT AGC CAG ATA GAG CTC AGG GTG CTG GCC CAC CTC TCC	1056
	Ala Leu Asp Tyr Ser Gln Ile Glu Leu Arg Val Leu Ala His Leu Ser	
	340 345 350	
35	GGC GAC GAG AAC CTG ATC CGG GTC TTC CAG GAG GGG CGG GAC ATC CAC	1104
	Gly Asp Glu Asn Leu Ile Arg Val Phe Gln Glu Gly Arg Asp Ile His	
	355 360 365	
40	ACG GAG ACC GCC AGC TGG ATG TTC GGC GTC CCC CGG GAG GCC GTG GAC	1152
	Thr Glu Thr Ala Ser Trp Met Phe Gly Val Pro Arg Glu Ala Val Asp	
	370 375 380	
45	CCC CTG ATG CGC CGG GCG GCC AAG ACC ATC AAC TAC GGG GTC CTC TAC	1200
	Pro Leu Met Arg Arg Ala Ala Lys Thr Ile Asn Tyr Gly Val Leu Tyr	
	385 390 395 400	
50	GGC ATG TCG GCC CAC CGC CTC TCC CAG GAG CTA GCC ATC CCT TAC GAG	1248
	Gly Met Ser Ala His Arg Leu Ser Gln Glu Leu Ala Ile Pro Tyr Glu	
	405 410 415	
55	GAG GCC CAG GCC TTC ATT GAG CGC TAC TTT CAG AGC TTC CCC AAG GTG	1296
	Glu Ala Gln Ala Phe Ile Glu Arg Tyr Phe Gln Ser Phe Pro Lys Val	
	420 425 430	
60	CGG GCC TGG ATT GAG AAG ACC CTG GAG GAG GGC AGG AGG CGG GGG TAC	1344
	Arg Ala Trp Ile Glu Lys Thr Leu Glu Glu Gly Arg Arg Gly Tyr	
	435 440 445	

EP 0 745 676 A1

5 GTG GAG ACC CTC TTC GGC CGC CGC CGC TAC GTG CCA GAC CTA GAG GCC 1392  
 Val Glu Thr Leu Phe Gly Arg Arg Arg Tyr Val Pro Asp Leu Glu Ala  
 450 455 460  
 10 CGG GTG AAG AGC GTG CGG GAG GCG GCC GAG CGC ATG GCC TTC AAC ATG 1440  
 Arg Val Lys Ser Val Arg Glu Ala Ala Glu Arg Met Ala Phe Asn Met  
 465 470 475 480  
 15 CCC GTC CAG GGC ACC GCC GCC GAC CTC ATG AAG CTG GCT ATG GTG AAG 1488  
 Pro Val Gln Gly Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val Lys  
 485 490 495  
 20 CTC TTC CCC AGG CTG GAG GAA ATG GGG GCC AGG ATG CTC CTT CAG GTC 1536  
 Leu Phe Pro Arg Leu Glu Glu Met Gly Ala Arg Met Leu Leu Gln Val  
 500 505 510  
 CAC GAC GAG CTG GTC CTC GAG GCC CCA AAA GAG AGG GCG GAG GCC GTG 1584  
 His Asp Glu Leu Val Leu Glu Ala Pro Lys Glu Arg Ala Glu Ala Val  
 515 520 525  
 25 GCC CGG CTG GCC AAG GAG GTC ATG GAG GGG GTG TAT CCC CTG GCC GTG 1632  
 Ala Arg Leu Ala Lys Glu Val Met Glu Gly Val Tyr Pro Leu Ala Val  
 530 535 540  
 30 CCC CTG GAG GTG GAG GTG GGG ATA GGG GAG GAC TGG CTC TCC GCC AAG 1680  
 Pro Leu Glu Val Glu Val Gly Ile Gly Glu Asp Trp Leu Ser Ala Lys  
 545 550 555 560  
 GAG TGA 1686  
 Glu \*

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1689 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ix) FEATURE:

(A) NAME/KEY: FY3  
 (B) LOCATION: 1...1686

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

ATG GCT CTG GAA CGT CTG GAG TTT GGC AGC CTC CTC CAC GAG TTC GGC 48

## EP 0 745 676 A1

	Met	Ala	Leu	Glu	Arg	Leu	Glu	Phe	Gly	Ser	Leu	Leu	His	Glu	Phe	Gly	
	1				5					10					15		
5	CTT	CTG	GAA	AGC	CCC	AAG	GCC	CTG	GAG	GAG	GCC	CCC	TGG	CCC	CCG	CCG	96
	Leu	Leu	Glu	Ser	Pro	Lys	Ala	Leu	Glu	Glu	Ala	Pro	Trp	Pro	Pro	Pro	
				20					25					30			
10	GAA	GGG	GCC	TTC	GTG	GGC	TTT	GTG	CTT	TCC	CGC	AAG	GAG	CCC	ATG	TGG	144
	Glu	Gly	Ala	Phe	Val	Gly	Phe	Val	Leu	Ser	Arg	Lys	Glu	Pro	Met	Trp	
			35					40					45				
15	GCC	GAT	CTT	CTG	GCC	CTG	GCC	GCC	GCC	AGG	GGG	GGC	CGG	GTC	CAC	CGG	192
	Ala	Asp	Leu	Leu	Ala	Leu	Ala	Ala	Ala	Arg	Gly	Gly	Arg	Val	His	Arg	
		50					55					60					
20	GCC	CCC	GAG	CCT	TAT	AAA	GCC	CTC	AGG	GAC	CTG	AAG	GAG	GCG	CGG	GGG	240
	Ala	Pro	Glu	Pro	Tyr	Lys	Ala	Leu	Arg	Asp	Leu	Lys	Glu	Ala	Arg	Gly	
	65					70				75					80		
25	CTT	CTC	GCC	AAA	GAC	CTG	AGC	GTT	CTG	GCC	CTG	AGG	GAA	GGC	CTT	GGC	288
	Leu	Leu	Ala	Lys	Asp	Leu	Ser	Val	Leu	Ala	Leu	Arg	Glu	Gly	Leu	Gly	
				85					90					95			
30	CTC	CCG	CCC	GGC	GAC	GAC	CCC	ATG	CTC	CTC	GCC	TAC	CTC	CTG	GAC	CCT	336
	Leu	Pro	Pro	Gly	Asp	Asp	Pro	Met	Leu	Leu	Ala	Tyr	Leu	Leu	Asp	Pro	
				100					105					110			
35	TCC	AAC	ACC	ACC	CCC	GAG	GGG	GTG	GCC	CGG	CGC	TAC	GGC	GGG	GAG	TGG	384
	Ser	Asn	Thr	Thr	Pro	Glu	Gly	Val	Ala	Arg	Arg	Tyr	Gly	Gly	Glu	Trp	
			115					120					125				
40	ACG	GAG	GAG	GCG	GGG	GAG	CGG	GCC	GCC	CTT	TCC	GAG	AGG	CTC	TTC	GCC	432
	Thr	Glu	Glu	Ala	Gly	Glu	Arg	Ala	Ala	Leu	Ser	Glu	Arg	Leu	Phe	Ala	
		130					135					140					
45	AAC	CTG	TGG	GGG	AGG	CTT	GAG	GGG	GAG	GAG	AGG	CTC	CTT	TGG	CTT	TAC	480
	Asn	Leu	Trp	Gly	Arg	Leu	Glu	Gly	Glu	Glu	Arg	Leu	Leu	Trp	Leu	Tyr	
	145					150					155				160		
50	CGG	GAG	GTG	GAG	AGG	CCC	CTT	TCC	GCT	GTC	CTG	GCC	CAC	ATG	GAG	GCC	528
	Arg	Glu	Val	Glu	Arg	Pro	Leu	Ser	Ala	Val	Leu	Ala	His	Met	Glu	Ala	
				165					170					175			
55	ACG	GGG	GTG	CGC	CTG	GAC	GTG	GCC	TAT	CTC	AGG	GCC	TTG	TCC	CTG	GAG	576
	Thr	Gly	Val	Arg	Leu	Asp	Val	Ala	Tyr	Leu	Arg	Ala	Leu	Ser	Leu	Glu	
			180					185					190				
60	GTG	GCC	GAG	GAG	ATC	GCC	CGC	CTC	GAG	GCC	GAG	GTC	TTC	CGC	CTG	GCC	624
	Val	Ala	Glu	Glu	Ile	Ala	Arg	Leu	Glu	Ala	Glu	Val	Phe	Arg	Leu	Ala	
		195					200					205					
65	GGC	CAC	CCC	TTC	AAC	CTC	AAC	TCC	CGG	GAC	CAG	CTG	GAA	AGG	GTC	CTC	672

EP 0 745 676 A1

	Gly	His	Pro	Phe	Asn	Leu	Asn	Ser	Arg	Asp	Gln	Leu	Glu	Arg	Val	Leu	
	210						215					220					
5	TTT	GAC	GAG	CTA	GGG	CTT	CCC	GCC	ATC	GGC	AAG	ACG	GAG	AAG	ACC	GGC	720
	Phe	Asp	Glu	Leu	Gly	Leu	Pro	Ala	Ile	Gly	Lys	Thr	Glu	Lys	Thr	Gly	
	225					230					235					240	
10	AAG	CGC	TCC	ACC	AGC	GCC	GCC	GTC	CTG	GAG	GCC	CTC	CGC	GAG	GCC	CAC	768
	Lys	Arg	Ser	Thr	Ser	Ala	Ala	Val	Leu	Glu	Ala	Leu	Arg	Glu	Ala	His	
					245					250					255		
15	CCC	ATC	GTG	GAG	AAG	ATC	CTG	CAG	TAC	CGG	GAG	CTC	ACC	AAG	CTG	AAG	816
	Pro	Ile	Val	Glu	Lys	Ile	Leu	Gln	Tyr	Arg	Glu	Leu	Thr	Lys	Leu	Lys	
					260					265					270		
20	AGC	ACC	TAC	ATT	GAC	CCC	TTG	CCG	GAC	CTC	ATC	CAC	CCC	AGG	ACG	GGC	864
	Ser	Thr	Tyr	Ile	Asp	Pro	Leu	Pro	Asp	Leu	Ile	His	Pro	Arg	Thr	Gly	
					275					280				285			
25	CGC	CTC	CAC	ACC	CGC	TTC	AAC	CAG	ACG	GCC	ACG	GCC	ACG	GGC	AGG	CTA	912
	Arg	Leu	His	Thr	Arg	Phe	Asn	Gln	Thr	Ala	Thr	Ala	Thr	Gly	Arg	Leu	
							295					300					
30	AGT	AGC	TCC	GAT	CCC	AAC	CTC	CAG	AAC	ATC	CCC	GTC	CGC	ACC	CCG	CTT	960
	Ser	Ser	Ser	Asp	Pro	Asn	Leu	Gln	Asn	Ile	Pro	Val	Arg	Thr	Pro	Leu	
	305					310					315					320	
35	GGG	CAG	AGG	ATC	CGC	CGG	GCC	TTC	ATC	GCC	GAG	GAG	GGG	TGG	CTA	TTG	1008
	Gly	Gln	Arg	Ile	Arg	Arg	Ala	Phe	Ile	Ala	Glu	Glu	Gly	Trp	Leu	Leu	
					325					330					335		
40	GTG	GCC	CTG	GAC	TAT	AGC	CAG	ATA	GAG	CTC	AGG	GTG	CTG	GCC	CAC	CTC	1056
	Val	Ala	Leu	Asp	Tyr	Ser	Gln	Ile	Glu	Leu	Arg	Val	Leu	Ala	His	Leu	
					340					345				350			
45	TCC	GGC	GAC	GAG	AAC	CTG	ATC	CGG	GTC	TTC	CAG	GAG	GGG	CGG	GAC	ATC	1104
	Ser	Gly	Asp	Glu	Asn	Leu	Ile	Arg	Val	Phe	Gln	Glu	Gly	Arg	Asp	Ile	
					355					360				365			
50	CAC	ACG	GAG	ACC	GCC	AGC	TGG	ATG	TTC	GGC	GTC	CCC	CGG	GAG	GCC	GTG	1152
	His	Thr	Glu	Thr	Ala	Ser	Trp	Met	Phe	Gly	Val	Pro	Arg	Glu	Ala	Val	
					370					375				380			
55	GAC	CCC	CTG	ATG	CGC	CGG	GCG	GCC	AAG	ACC	ATC	AAC	TAC	GGG	GTC	CTC	1200
	Asp	Pro	Leu	Met	Arg	Arg	Ala	Ala	Lys	Thr	Ile	Asn	Tyr	Gly	Val	Leu	
	385					390					395					400	
60	TAC	GGC	ATG	TCG	GCC	CAC	CGC	CTC	TCC	CAG	GAG	CTA	GCC	ATC	CCT	TAC	1248
	Tyr	Gly	Met	Ser	Ala	His	Arg	Leu	Ser	Gln	Glu	Leu	Ala	Ile	Pro	Tyr	
					405					410				415			

EP 0 745 676 A1

5	GAG GAG GCC CAG GCC TTC ATT GAG CGC TAC TTT CAG AGC TTC CCC AAG	1296
	Glu Glu Ala Gln Ala Phe Ile Glu Arg Tyr Phe Gln Ser Phe Pro Lys	
	420 425 430	
10	GTG CGG GCC TGG ATT GAG AAG ACC CTG GAG GAG GGC AGG AGG CGG GGG	1344
	Val Arg Ala Trp Ile Glu Lys Thr Leu Glu Glu Gly Arg Arg Arg Gly	
	435 440 445	
15	TAC GTG GAG ACC CTC TTC GGC CGC CGC CGC TAC GTG CCA GAC CTA GAG	1392
	Tyr Val Glu Thr Leu Phe Gly Arg Arg Arg Tyr Val Pro Asp Leu Glu	
	450 455 460	
20	GCC CGG GTG AAG AGC GTG CGG GAG GCG GCC GAG CGC ATG GCC TTC AAC	1440
	Ala Arg Val Lys Ser Val Arg Glu Ala Ala Glu Arg Met Ala Phe Asn	
	465 470 475 480	
25	ATG CCC GTC CAG GGC ACC GCC GCC GAC CTC ATG AAG CTG GCT ATG GTG	1488
	Met Pro Val Gln Gly Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val	
	485 490 495	
30	AAG CTC TTC CCC AGG CTG GAG GAA ATG GGG GCC AGG ATG CTC CTT CAG	1536
	Lys Leu Phe Pro Arg Leu Glu Glu Met Gly Ala Arg Met Leu Leu Gln	
	500 505 510	
35	GTC CAC GAC GAG CTG GTC CTC GAG GCC CCA AAA GAG AGG GCG GAG GCC	1584
	Val His Asp Glu Leu Val Leu Glu Ala Pro Lys Glu Arg Ala Glu Ala	
	515 520 525	
40	GTG GCC CGG CTG GCC AAG GAG GTC ATG GAG GGG GTG TAT CCC CTG GCC	1632
	Val Ala Arg Leu Ala Lys Glu Val Met Glu Gly Val Tyr Pro Leu Ala	
	530 535 540	
45	GTG CCC CTG GAG GTG GAG GTG GGG ATA GGG GAG GAC TGG CTC TCC GCC	1680
	Val Pro Leu Glu Val Glu Val Gly Ile Gly Glu Asp Trp Leu Ser Ala	
	545 550 555 560	
50	AAG GAG TGA	1689
	Lys Glu *	

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

(A)	LENGTH:	23 base pairs
(B)	TYPE:	nucleic acid
(C)	STRANDEDNESS:	single
(D)	TOPOLOGY:	linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:



GCTTGGGCAG AGGATCCGCC GGG

23

5

(2) INFORMATION FOR SEQ ID NO: 4:

10

(i) SEQUENCE CHARACTERISTICS:

15

(A) LENGTH: 64 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

20

GGGATGGCTA GCTCCTGGGA GAGGCGGTGG GCCGACATGC CGTAGAGGAC  
CCCGTAGTTG ATGG

50  
64

25

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

30

(A) LENGTH: 31 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

GGAATTCCAT ATGGACGATC TGAAGCTCTC C

31

40

(2) INFORMATION FOR SEQ ID NO: 6:

45

(i) SEQUENCE CHARACTERISTICS:

50

(A) LENGTH: 31 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

55

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

GGGGTACCAA GCTTCACTCC TTGGCGGAGA G

31

(2) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 31 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

GGAATTCCAT ATGCTGGAGA GGCTTGAGTT T

31

(2) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 43 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

GGAATTCCAT ATGCTGGAAC GTCTGGAGTT TGGCAGCCTC CTC

43

(2) INFORMATION FOR SEQ ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 46 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

GGAATTCCAT ATGGCTCTGG AACGTCTGGA GTTTGGCAGC CTCCTC

46

5 (2) INFORMATION FOR SEQ ID NO: 10:

(i) SEQUENCE CHARACTERISTICS:

10 (A) LENGTH: 40 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
15 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

GGAATTCCAT ATGCTGGAAC GTCTGGAATT CGGCAGCCTC

40

20 (2) INFORMATION FOR SEQ ID NO: 11:

25 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 32 base pairs  
(B) TYPE: nucleic acid  
30 (C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

GGGGTACCCT AACCCCTTGGC GGAAAGCCAG TC

32

40 (2) INFORMATION FOR SEQ ID NO: 12:

(i) SEQUENCE CHARACTERISTICS:

45 (A) LENGTH: 64 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
50 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

GGGATGGCTA GCTCCTGGGA GAGCCTATGG GCGGACATGC CGTAGAGGAC

50

GCCGTAGTTC ACCG

64

## (2) INFORMATION FOR SEQ ID NO: 13:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 35 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

CTAGCTAGCC ATCCCCTACG AAGAAGCGGT GGCCT

35

## (2) INFORMATION FOR SEQ ID NO: 14:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1686 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

## (ix) FEATURE:

(A) NAME/KEY: FY4  
 (B) LOCATION: 1...1683

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

ATG CTG GAA CGT CTG GAA TTC GGC AGC CTC CTC CAC GAG TTC GGC CTC  
 Met Leu Glu Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly Leu  
 1 5 10 15

48

CTG GAG GCC CCC GCC CCC CTG GAG GAG GCC CCC TGG CCC CCG CCG GAA  
 Leu Glu Ala Pro Ala Pro Leu Glu Glu Ala Pro Trp Pro Pro Pro Glu  
 20 25 30

96

GGG GCC TTC GTG GGC TTC GTC CTC TCC CGC CCC GAG CCC ATG TGG GCG  
 Gly Ala Phe Val Gly Phe Val Leu Ser Arg Pro Glu Pro Met Trp Ala  
 35 40 45

144

EP 0 745 676 A1

	GAG CTT AAA GCC CTG GCC GCC TGC AGG GAC GGC CGG GTG CAC CGG GCA	192
	Glu Leu Lys Ala Leu Ala Ala Cys Arg Asp Gly Arg Val His Arg Ala	
	50 55 60	
5	GCA GAC CCC TTG GCG GGG CTA AAG GAC CTC AAG GAG GTC CGG GGC CTC	240
	Ala Asp Pro Leu Ala Gly Leu Lys Asp Leu Lys Glu Val Arg Gly Leu	
	65 70 75 80	
10	CTC GCC AAG GAC CTC GCC GTC TTG GCC TCG AGG GAG GGG CTA GAC CTC	288
	Leu Ala Lys Asp Leu Ala Val Leu Ala Ser Arg Glu Gly Leu Asp Leu	
	85 90 95	
15	GTG CCC GGG GAC GAC CCC ATG CTC CTC GCC TAC CTC CTG GAC CCC TCC	336
	Val Pro Gly Asp Asp Pro Met Leu Leu Ala Tyr Leu Leu Asp Pro Ser	
	100 105 110	
20	AAC ACC ACC CCC GAG GGG GTG GCG CGG CGC TAC GGG GGG GAG TGG ACG	384
	Asn Thr Thr Pro Glu Gly Val Ala Arg Arg Tyr Gly Gly Glu Trp Thr	
	115 120 125	
25	GAG GAC GCC GCC CAC CGG GCC CTC CTC TCG GAG AGG CTC CAT CGG AAC	432
	Glu Asp Ala Ala His Arg Ala Leu Leu Ser Glu Arg Leu His Arg Asn	
	130 135 140	
30	CTC CTT AAG CGC CTC GAG GGG GAG GAG AAG CTC CTT TGG CTC TAC CAC	480
	Leu Leu Lys Arg Leu Glu Gly Glu Glu Lys Leu Leu Trp Leu Tyr His	
	145 150 155 160	
35	GAG GTG GAA AAG CCC CTC TCC CGG GTC CTG GCC CAC ATG GAG GCC ACC	528
	Glu Val Glu Lys Pro Leu Ser Arg Val Leu Ala His Met Glu Ala Thr	
	165 170 175	
40	GGG GTA CGG CTG GAC GTG GCC TAC CTT CAG GCC CTT TCC CTG GAG CTT	576
	Gly Val Arg Leu Asp Val Ala Tyr Leu Gln Ala Leu Ser Leu Glu Leu	
	180 185 190	
45	GCG GAG GAG ATC CGC CGC CTC GAG GAG GAG GTC TTC CGC TTG GCG GGC	624
	Ala Glu Glu Ile Arg Arg Leu Glu Glu Glu Val Phe Arg Leu Ala Gly	
	195 200 205	
50	CAC CCC TTC AAC CTC AAC TCC CGG GAC CAG CTG GAA AGG GTG CTC TTT	672
	His Pro Phe Asn Leu Asn Ser Arg Asp Gln Leu Glu Arg Val Leu Phe	
	210 215 220	
55	GAC GAG CTT AGG CTT CCC GCC TTG GGG AAG ACG CAA AAG ACA GGC AAG	720
	Asp Glu Leu Arg Leu Pro Ala Leu Gly Lys Thr Gln Lys Thr Gly Lys	
	225 230 235 240	
60	CGC TCC ACC AGC GCC GCG GTG CTG GAG GCC CTA CGG GAG GCC CAC CCC	768
	Arg Ser Thr Ser Ala Ala Val Leu Glu Ala Leu Arg Glu Ala His Pro	
	245 250 255	
65	ATC GTG GAG AAG ATC CTC CAG CAC CGG GAG CTC ACC AAG CTC AAG AAC	816

EP 0 745 676 A1

	Ile Val Glu Lys Ile Leu Gln His Arg Glu Leu Thr Lys Leu Lys Asn	
	260 265 270	
5	ACC TAC GTG GAC CCC CTC CCA AGC CTC GTC CAC CCG AGG ACG GGC CGC Thr Tyr Val Asp Pro Leu Pro Ser Leu Val His Pro Arg Thr Gly Arg	864
	275 280 285	
10	CTC CAC ACC CGC TTC AAC CAG ACG GCC ACG GCC ACG GGG AGG CTT AGT Leu His Thr Arg Phe Asn Gln Thr Ala Thr Ala Thr Gly Arg Leu Ser	912
	290 295 300	
15	AGC TCC GAC CCC AAC CTG CAG AAC ATC CCC GTC CGC ACC CCC TTG GGC Ser Ser Asp Pro Asn Leu Gln Asn Ile Pro Val Arg Thr Pro Leu Gly	960
	305 310 315 320	
20	CAG AGG ATC CGC CGG GCC TTC GTG GCC GAG GCG GGT TGG GCG TTG GTG Gln Arg Ile Arg Arg Ala Phe Val Ala Glu Ala Gly Trp Ala Leu Val	1008
	325 330 335	
25	GCC CTG GAC TAT AGC CAG ATA GAG CTC CGC GTC CTC GCC CAC CTC TCC Ala Leu Asp Tyr Ser Gln Ile Glu Leu Arg Val Leu Ala His Leu Ser	1056
	340 345 350	
30	GGG GAC GAA AAC CTG ATC AGG GTC TTC CAG GAG GGG AAG GAC ATC CAC Gly Asp Glu Asn Leu Ile Arg Val Phe Gln Glu Gly Lys Asp Ile His	1104
	355 360 365	
35	ACC CAG ACC GCA AGC TGG ATG TTC GGC GTC CCC CCG GAG GCC GTG GAC Thr Gln Thr Ala Ser Trp Met Phe Gly Val Pro Pro Glu Ala Val Asp	1152
	370 375 380	
40	CCC CTG ATG CGC CGG GCG GCC AAG ACG GTG AAC TAC GGC GTC CTC TAC Pro Leu Met Arg Arg Ala Ala Lys Thr Val Asn Tyr Gly Val Leu Tyr	1200
	385 390 395 400	
45	GGC ATG TCC GCC CAT AGG CTC TCC CAG GAG CTA GCC ATC CCC TAC GAA Gly Met Ser Ala His Arg Leu Ser Gln Glu Leu Ala Ile Pro Tyr Glu	1248
	405 410 415	
50	GAA GCG GTG GCC TTT ATA GAG CGC TAC TTC CAA AGC TTC CCC AAG GTG Glu Ala Val Ala Phe Ile Glu Arg Tyr Phe Gln Ser Phe Pro Lys Val	1296
	420 425 430	
55	CGG GCC TGG ATA GAA AAG ACC CTG GAG GAG GGG AGG AAG CGG GGC TAC Arg Ala Trp Ile Glu Lys Thr Leu Glu Glu Gly Arg Lys Arg Gly Tyr	1344
	435 440 445	
60	GTG GAA ACC CTC TTC GGA AGA AGG CGC TAC GTG CCC GAC CTC AAC GCC Val Glu Thr Leu Phe Gly Arg Arg Arg Tyr Val Pro Asp Leu Asn Ala	1392
	450 455 460	
65	CGG GTG AAG AGC GTC AGG GAG GCC GCG GAG CGC ATG GCC TTC AAC ATG Arg Val Lys Ser Val Arg Glu Ala Ala Glu Arg Met Ala Phe Asn Met	1440

	465	470	475	480	
5	CCC GTC CAG GGC ACC GCC GCC GAC CTC ATG AAG CTC GCC ATG GTG AAG				1488
	Pro Val Gln Gly Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val Lys				
		485	490	495	
10	CTC TTC CCC CGC CTC CGG GAG ATG GGG GCC CGC ATG CTC CTC CAG GTC				1536
	Leu Phe Pro Arg Leu Arg Glu Met Gly Ala Arg Met Leu Leu Gln Val				
		500	505	510	
15	CAC GAC GAG CTC CTC CTG GAG GCC CCC CAA GCG CGG GCC GAG GAG GTG				1584
	His Asp Glu Leu Leu Leu Glu Ala Pro Gln Ala Arg Ala Glu Glu Val				
		515	520	525	
20	GCG GCT TTG GCC AAG GAG GCC ATG GAG AAG GCC TAT CCC CTC GCC GTG				1632
	Ala Ala Leu Ala Lys Glu Ala Met Glu Lys Ala Tyr Pro Leu Ala Val				
		530	535	540	
25	CCC CTG GAG GTG GAG GTG GGG ATG GGG GAG GAC TGG CTT TCC GCC AAG				1680
	Pro Leu Glu Val Glu Val Gly Met Gly Glu Asp Trp Leu Ser Ala Lys				
		545	550	555	560
30	GGT TAG				1686
	Gly *				

#### Claims

- 35 1. An enzymatically active DNA polymerase having between 540 and 582 amino acids having a tyrosine at a position equivalent to position 667 of Taq DNA polymerase, wherein said polymerase lacks 5' to 3' exonuclease activity, and wherein said polymerase has at least 95% homology in its amino acid sequence to the DNA polymerase of Thermus aquaticus, Thermus flavus or Thermus thermophilus, and wherein said polymerase forms a single polypeptide band or an SDS polyacrylamide gel.
- 40 2. The polymerase of claim 1 wherein the amino acid sequence of said polymerase includes less than 3 conservative amino acid changes compared to one said DNA polymerase of said named Thermus species.
- 45 3. The polymerase of claim 1 wherein the amino acid sequence of said polymerase includes less than 3 additional amino acids compared to one said DNA polymerase of said named Thermus species at its N-terminus.
4. The polymerase of claim 1 selected from the group consisting of FY2, FY3 and FY4.
- 50 5. Purified nucleic acid encoding the DNA polymerase of any of claims 1-4.
6. Method for sequencing DNA comprising the step of generating chain terminated fragments from the DNA template to be sequenced with a DNA polymerase of any of claims 1-4 in the presence of at least one chain terminating agent and one or more nucleotide triphosphates, and determining the sequence of said DNA from the sizes of said fragments.
- 55 7. Kit for sequencing DNA comprising a DNA polymerase of any of claims 1-4 and a pyrophosphatase.
8. The kit of claim 7 wherein said pyrophosphatase is thermostable.

9. Apparatus for DNA sequencing having a reactor comprising a DNA polymerase of any of claims 1-4 and a band separator.

5

10

15

20

25

30

35

40

45

50

55



FIG. 1  
(sheet 1)

▲ DNA sequence 1686 b.p. atgctggagagg ... gcccaaggagtga linear

1/1 31/11  
atg ctg gag agg ctt gag ttt ggc agc ctc ctc cac gag ttc ggc ctt ctg gaa agc ccc  
M L E R L E F G S L L H E F G L L E S P

61/21 91/31  
aag gcc ctg gag gag gcc ccc tgg ccc ccg ccg gaa ggg gcc ttc gtc ggc ttt gtc ctt  
K A L E E A P W P P P E G A F V G F V L

121/41 151/51  
ccc cgc aag gag ccc atg tgg gcc gat ctt ctg gcc ctc gcc gcc agg ggg ggc cgg  
S R K E P M W A D L L A L A A A R G G R

181/61 211/71  
gtc cac cgg gcc ccc gag cct tat aaa gcc ctc agg gac ctg aag gag ggc cgg ggg ctc  
V H R A P E P Y K A L R D L K E A R G L

241/81 271/91  
ctc gcc aaa gac ctg agc gtt ctg gcc ctg agg gaa ggc ctt ggc ctc ccg ccc ggc gac  
L A K D L S V L A L R E G L G L P P G D

301/101 331/111  
gac ccc atg ctc ctc gcc tac ctc ctg gac cct tcc aac acc acc ccc gag ggg gtc gcc  
D P M L L A Y L L D P S N T T P E G V A

361/121 391/131  
cgg cgc tac ggc ggg gag tgg acg gag gag gcg ggg gag cgg gcc gcc ctt tcc gag agg  
R R Y G G E W T E E A G E R A A L S E R

421/141 451/151  
ctc ttc gcc aac ctg tgg ggg agg ctt gag ggg gag gag agg ctc ctt tgg ctt tac cgg  
L F A N L W G R L E G E E R L L W L Y R

481/161 511/171  
gag gtc gag agg ccc ctt tcc gct gtc ctg gcc cac atg gag gcc acg ggg gtc cgc ctg  
E V E R P L S A V L A H M E A T G V R L

541/181 571/191  
gac gtc gcc tat ctc agg gcc ttg tcc ctg gag gtc gcc gag gag atc gcc cgc ctc gag  
D V A Y L R A L S L E V A E E I A R L E

601/201 631/211  
gcc gag gtc ttc cgc ctg gcc ggc cac ccc ttc aac ctc aac tcc cgg gac cag ctg gaa  
A E V F R L A G H P F N L N S R D Q L E

661/221 691/231  
agg gtc ctc ttt gag gag cta ggg ctt ccc gcc atc ggc aag acg gag aag acc ggc aag  
R V L F D E L G L P A I G K T E K T G K

721/241 751/251  
cgc tcc acc agc gcc gcc gtc ctg gag gcc ctc cgc gag gcc cac ccc atc gtc gag aag  
R S T S A A A G V L E A L R E A H P I V E K

781/261 811/271  
atc ctg cag tac cgg gag ctc acc aag ctg aag agc acc tac att gac ccc ttg ccg gac  
I L Q Y R E L T K L K S T Y I D P L P D

841/281 871/291  
ctc atc cac ccc agg acg ggc cgc ctc cac acc cgc ttc aac cag acg gcc acg gcc acg  
L I H P R T G R L H T R F N Q T A T A T

901/301 931/311  
ggc agg cta agt agc tcc gat ccc aac ctc cag aac atc ccc gtc cgc acc ccg ctt ggg  
G R L S S S D P N L Q N I P V R T P L G

961/321 991/331  
cag agg atc cgc cgg gcc ttc atc gcc gag gag ggg tgg cta ttg gtc gcc ctg gac tat  
Q R I R R A F I A E E G W L L V A L D Y

1021/341 1051/351  
agc cag ata gag ctc agg gtc ctg gcc cac ctc tcc ggc gac gag aac ctg atc cgg gtc  
S Q I E L R V L A H L S G D E N L I R V

1081/361 1111/371  
ttc cag gag ggg cgg gac atc cac acg gag acc gcc agc tgg atg ttc ggc gtc ccc cgg  
F Q E G R D I H T E T A S W M F G V P R

1141/381 1171/391  
gag gcc gtc gac ccc ctg atg cgc cgg ggc gcc aag acc atc aac tac ggg gtc ctc tac  
E A V D P L M R R A A K T I N Y G V L Y

1201/401 1231/411  
ggc atg tgc gcc cac cgc ctc tcc cag gag cta gcc atc cct tac gag gag gcc cag gcc  
G M S A H R I C O T

1261/421	1291/431
ttc att gag cgc tac ttt cag agc ttc ccc	aag gtg cgg gcc tgg att gag aag acc ctg
F I E R Y F Q S F P	K V R A W I E K T L
1321/441	1351/451
gag gag gcc agg agg cgg ggg tac gtg gag	acc ctg ttc ggc cgc cgc cgc tac gtg cca
E E G R R R G Y V E	T L F G R R R Y V P
1381/461	1411/471
gac cta gag gcc cgg gtg aag agc gtg cgg	gag gcg gcc gag cgc atg gcc ttc aac atg
D L E A R V K S V R	E A A E R M A F N M
1441/481	1471/491
ccc gtc cag gcc acc gcc gcc gac ctg atg	aag ctg gct atg gtg aag ctg ttc ccc agg
P V Q G T A A D L M	K L A M V K L F P R
1501/501	1531/511
ctg gag gaa atg ggg gcc agg atg ctg ctt	cag gtc cac gac gag ctg gtc ctg gag gcc
L E E M G A R M L L	Q V H D E L V L E A
1561/521	1591/531
cca aaa gag agg gcg gag gcc gtg gcc cgg	ctg gcc aag gag gtc atg gag ggg gtg tac
P K E R A E A V A R	L A K E V M E G V Y
1621/541	1651/551
ccc ctg gcc gtg ccc ctg gag gtg gag gtg	ggg ata ggg gag gac tgg ctg tcc gcc aag
P L A V P L E V E V	G I G E D W L S A K
1681/561	
gag tga	
E	

FIG. 1  
(sheet 2)

FIG. 2  
(sheet 1)

DNA sequence 1689 b.p. atggctctggaa ... gccaaggagtga linear

```

1/1                               31/11
atg gct ctg gaa cgt ctg gag ttt ggc agc ctc ctc cac gag ttc ggc ctt ctg gaa agc
M A L E R L E F G S L L H E F G L L E S
61/21                               91/31
ccc aag gcc ctg gag gag gcc ccc tgg ccc ccg ccg gaa ggg gcc ttc gtg ggc ttt gtg
P K A L E E A P W P P P E G A F V G F V
121/41                               151/51
ctt tcc cgc aag gag ccc atg tgg gcc gat ctt ctg gcc ctg gcc gcc gcc agg ggg ggc
L S R K E P M W A D L L A L A A A R G G
181/61                               211/71
cgg gtc cac cgg gcc ccc gag cct tat aaa gcc ctc agg gac ctg aag gag gcg cgg ggg
R V H R A P E P Y K A L R D L K E A R G
241/81                               271/91
ctt ctc gcc aaa gac ctg agc gtt ctg gcc ctg agg gaa ggc ctt ggc ctc ccg ccc ggc
L L A K D L S V L A L R E G L G L P P G
301/101                               331/111
gac gac gcc ccc atg ctc ctc gcc tac ctc ctg gac cct tcc aac acc acc ccc gag ggg gtg
D D P M L L A Y L L D P S N T T P E G V
361/121                               391/131
gcc cgg cgc tac ggc ggg gag tgg acg gag gag gcg ggg gag cgg gcc gcc ctt tcc gag
A R R Y G G E W T E E A G E R A A L S E
421/141                               451/151
agg ctc ttc gcc aac ctg tgg ggg agg ctt gag ggg gag gag agg ctc ctt tgg ctt tac
R L F A N L W G R L E G E E R L L W L Y
481/161                               511/171
cgg gag gtg gag agg ccc ctt tcc gct gtc ctg gcc cac atg gag gcc acg ggg gtg cgc
R E V E R P L S A V L A H H E A T G V R
541/181                               571/191
ctg gac gtg gcc tat ctc agg gcc ttg tcc ctg gag gtg gcc gag gag atc gcc cgc ctc
L D V A Y L R A L S L E V A E E I A R L
601/201                               631/211
gag gcc gag gtc ttc cgc ctg gcc ggc cac ccc ttc aac ctc aac tcc cgg gac cag ctg
E A E V F R L A G H P F N L N S R D Q L
661/221                               691/231
gaa agg gtc ctc ttt gac gag cta ggg ctt ccc gcc atc ggc aag acg gag aag acc ggc
E R V L F D E L G L P A I G K T E K T G
721/241                               751/251
aag cgc tcc acc agc gcc gcc gtc ctg gag gcc ctc cgc gag gcc cac ccc atc gtg gag
K R S T S A A V L E A L R E A H P I V E
781/261                               811/271
aag atc ctg cag tac cgg gag ctc acc aag ctg aag agc acc tac att gac ccc ttg cgg
K I L Q Y R E L T K L K S T Y I D P L P
841/281                               871/291
gac ctc atc cac ccc agg acg ggc cgc ctc cac acc cgc ttc aac cag acg gcc acg gcc
D L I H P R T G R L H T R F N Q T A T A
901/301                               931/311
acg ggc agg cta agt agc tcc gat ccc aac ctc cag aac atc ccc gtc cgc acc ccg ctt
T G R L S S S D P N L Q N I P V R T P L
961/321                               991/331
ggg cag agg atc cgc cgg gcc ttc atc gcc gag gag ggg tgg cta ttg gtg gcc ctg gac
G Q R I R R A F I A E E G W L L V A L D
1021/341                               1051/351
tat agc cag ata gag ctc agg gtg ctg gcc cac ctc tcc ggc gac gag aac ctg atc cgg
Y S Q I E L R V L A H L S G D E N L I R
1081/361                               1111/371
gtc ttc cag gag ggg cgg gac atc cac acg gag acc gcc agc tgg atg ttc ggc gtc ccc
V F Q E G R D I H T E T A S W H F G V P
1141/381                               1171/391
cgg gag gcc gtg gac ccc ctg atg cgc cgg gcg gcc aag acc atc aac tac ggg gtc ctc
R E A V D P L M R R A A K T I N Y G V L
1201/401                               1231/411
tac ggc atg tgg gcc cac cgc ctc tcc cag gag cta gcc atc cct tac gag gag gcc cag
Y G M S A H R L S Q E L A I P Y E E A Q

```

1261/421	1291/431
gcc ttc att gag cgc tac ttt cag agc ttc	ccc aag gtg cgg gcc tgg att gag aag acc
A F I E R Y F Q S F	P K V R A W I E K T
1321/441	1351/451
atg gag gag gcc agg agg cgg ggg tac gtg	gag acc ctc ttc ggc cgc cgc cgc tac gtg
L E E G R R R G Y V	E T L F G R R R Y V
1381/461	1411/471
cca gac cta gag gcc cgg gtg aag agc gtg	cgg gag gcg gcc gag cgc atg gcc ttc aac
P D L E A R V K S V	R E A A E R M A F N
1441/481	1471/491
atg ccc gtc cag ggc acc gcc gcc gac ctc	atg aag ctg gct atg gtg aag ctc ttc ccc
M P V Q G T A A D L	H K L A M V K L F P
1501/501	1531/511
agg ctg gag gaa atg ggg gcc agg atg ctc	ctt cag gtc cac gac gag ctg gtc ctc gag
R L E E M G A R M L	L Q V H D E L V L E
1561/521	1591/531
gcc cca aaa gag agg gcg gag gcc gtg gcc	cgg ctg gcc aag gag gtc atg gag ggg gtg
A P K E R A E A V A	R L A K E V M E G V
1621/541	1651/551
tat ccc ctg gcc gtg ccc ctg gag gtg gag	gtg ggg ata ggg gag gac tgg ctc tcc gcc
Y P L A V P L E V E	V G I G E D W L S A
1681/561	
aag gag tga	
K E *	

FIG. 2  
(sheet 2)

FIG. 3  
(sheet 1)

DNA sequence 2496 b.p. atggcgatgctt ... gcccaaggagtag linear

```

1/1                               31/11
atg gcg atg ctt ccc ctc ttt gag ccc aaa ggc cgc gtg ctc ctg gtg gac ggc cac cac
M A M L P L F E P K G R V L L V D G H H
61/21                               91/31
ctg gcc tac cgc acc ttc ttt gcc ctc aag ggc ctc acc acc agc cgc ggc gaa ccc gtt
L A Y R T F F A L K G L T T S R G E P V
121/41                               151/51
cag gcg gtc tac ggc ttc gcc aaa agc ctc ctc aag gcc ctg aag gag gac ggg gac gtg
Q A V Y G F A K S L L K A L K E D G D V
181/61                               211/71
gtg gtg gtg gtc ttt gac gcc aag gcc ccc tcc ttc cgc cac gag gcc tac gag gcc tac
V V V V F D A K A P S F R H E A Y E A Y
241/81                               271/91
aag gcg ggc cgc gcc ccc acc ccg gag gac ttt ccc cgc cag ctg gcc ctc atc aag gag
K A G R A P T P E D F P R Q L A L I K E
301/101                               331/111
ttg gtg gac ctc cta ggc ctt gtg cgg ctg gag gtt ccc ggc ttt gag gcg gac gac gtg
L V D L L G L V R L E V P G F E A D D V
361/121                               391/131
ctg gcc acc ctg gcc aag cgg gcg gaa aag gag ggg tac gag gtg cgc atc ctc act gcc
L A T L A K R A E K E G Y E V R I L T A
421/141                               451/151
gac cgc gac ctc tac cag ctc ctt tgg gag cgc atc gcc atc ctc cac cct gag ggg tac
D R D L Y Q L L S E R I A I L H P E G Y
481/161                               511/171
ctg atc acc ccg gcg tgg ctt tac gag aag tac ggc ctg cgc ccg gag cag tgg gcg gac
L I T P A W L Y E K Y G L R P E Q W V D
541/181                               571/191
tac cgg gcc ctg gcg ggg gac ccc tgg gat aac atc ccc ggg gtg aag gcc atc ggg gag
Y R A L A G D P S D N I P G V K G I G E
601/201                               631/211
aag acc gcc cag agg ctc atc cgc gag tgg ggg agc ctg gaa aac ctc ttc cag cac ctg
K T A Q R L I R E W G S L E N L F Q H L
661/221                               691/231
gac cag gtg aag ccc tcc ttg cgg gag aag ctc cag gcg ggc atg gag gcc ctg gcc ctt
D Q V K P S L R E K L Q A G M E A L A L
721/241                               751/251
tcc cgg aag ctt tcc cag gtg cac act gac ctg ccc ctg gag gtg gac ttc ggg agg cgc
S R K L S Q V H T D L P L E V D F G R R
781/261                               811/271
cgc aca ccc aac ctg gag ggt ctg cgg gct ttt ttg gag cgg ttg gag ttt gga agc ctc
R T P N L E G L R A F L E R L E F G S L
841/281                               871/291
ctc cac gag ttc ggc ctc ctg gag ggg ccg aag gcg gca gag gag gcc ccc tgg ccc cct
L H E F G L L E G P K A A E E A P W P P
901/301                               931/311
ccg gaa ggg gct ttt ttg ggc ttt tcc ttt tcc cgt ccc gag ccc atg tgg gcc gag ctt
P E G A F L G F S F S R P E P H W A E L
961/321                               991/331
ctg gcc ctg gct ggg gcg tgg gag ggg cgc ctc cat cgg gca caa gac ccc ctt agg ggc
L A L A G A W E G R L H R A Q D P L R G
1021/341                               1051/351
ctg agg gac ctt aag ggg gtg cgg gga atc ctg gcc aag gac ctg gcg gtt ttg gcc ctg
L R D L K G V R G I L A K D L A V L A L
1081/361                               1111/371
cgg gag ggc ctg gac ctc ttc cca gag gac gac ccc atg ctc ctg gcc tac ctt ctg gac
R E G L D L F P E D D P H L L A Y L L D
1141/381                               1171/391
ccc tcc aac acc acc cct gag ggg gtg gcc cgg cgt tac ggg ggg gag tgg acg gag gat
P S N T T P E G V A R R Y G G E W T E D
1201/401                               1231/411
gcg ggg gag agg gcc ctc ctg gcc gag cgc ctc ttc cag acc cta aag gag cgc ctt aag
A G E R A L L A E R L F Q T L K E R L K

```

1261/421  
 gga gaa gaa cgc ctg ctt tgg ctt tac gag gag gtg gag aag ccg ctt tcc cgg gtg ttg  
 G E E R L L W L Y E E V E K P L S R V L  
 1321/441  
 gcc cgg atg gag gcc acg ggg gtc cgg ctg gag gtg gcc tac ctc cag gcc ctc tcc ctg  
 A R M E A T G V R L D V A Y L Q A L S L  
 1381/461  
 gag gtg gag gcg gag gtg cgc cag ctg gag gag gag gtc ttc cgc ctg gcc ggc cac ccc  
 E V E A E V R Q L E E E V F R L A G H P  
 1441/481  
 ttc aac ctc aac tcc cgc gac cag ctg gag cgg gtg ctc ttt gac gag ctg ggc ctg cct  
 F N L N S R D Q L E R V L F D E L G L P  
 1501/501  
 gcc atc gcc aag acg gag aag acg ggg aaa cgc tcc acc agc gct gcc gtg ctg gag gcc  
 A I G K T E K T G K R S T S A A V L E A  
 1561/521  
 ctg cga gag gcc cac ccc atc gtg gac cgc atc ctg cag tac cgg gag ctc acc aag ctc  
 L R E A H P I V D R I L Q Y R E L T K L  
 1621/541  
 aag aac acc tac ata gac ccc ctg ccc gcc ctg gtc cac ccc aag acc ggc cgg ctc cac  
 K N T Y I D P L P A L V H P K T G R L H  
 1681/561  
 acc cgc ttc aac cag acg gcc acc gcc acg ggc agg ctt tcc agc tcc gac ccc aac ctg  
 T R F N Q T A T A T G R L S S S D P N L  
 1741/581  
 cag aac atc ccc gtg cgc acc cct ctg ggc cag cgc atc cgc cga gcc ttc gtg gcc gag  
 Q N I P V R T P L G Q R I R R A F V A E  
 1801/601  
 gag ggc tgg gtg ctg gtg gtc ttg gac tac agc cag att gag ctt cgg gtc ctg gcc cac  
 E G W V L V V L D Y S Q I E L R V L A H  
 1861/621  
 ctc tcc ggg gac gag aac ctg atc cgg gtc ttc cag gag ggg agg gac atc cac acc cag  
 L S G D E N L I R V F Q E G R D I H T Q  
 1921/641  
 acc gcc agc tgg atg ttc ggc gtt tcc ccc gaa ggg gta gac cct ctg atg cgc cgg ggc  
 T A S W M F G V S P E G V D P L M R R A  
 1981/661  
 gcc aag acc atc aac ttc ggg gtg ctc tac ggc atg tcc gcc cac cgc ctc tcc ggg gag  
 A K T I N F G V L Y G M S A H R L S G E  
 2041/681  
 ctt tcc atc ccc tac gag gag gcg gtg gcc ttc att gag cgc tac ttc cag agc tac ccc  
 L S I P Y E E A V A F I E R Y F Q S Y P  
 2101/701  
 aag gtg cgg gcc tgg att gag ggg acc ctc gag gag ggc cgc cgg cgg ggg tat gtg gag  
 K V R A W I E G T L E E G R R R G Y V E  
 2161/721  
 acc ctc ttc ggc cgc cgg cgc tat gtg ccc gac ctc aac gcc cgg gtg aag agc gtg cgc  
 T L F G R R R Y V P D L N A R V K S V R  
 2221/741  
 gag gcg gcg gag cgc atg gcc ttc aac atg cgc gtc cag ggc acc gcc gcc gac ctc atg  
 E A A E R M A F N M P V Q G T A A D L M  
 2281/761  
 aag ctg gcc atg gtg cgg ctt ttc ccc cgg ctt cag gaa ctg ggg gcg agg atg ctt ttg  
 K L A M V R L F P R L Q E L G A R M L L  
 2341/781  
 cag gtg cac gac gag ctg gtc ctc gag gcc ccc aag gac cgg gcg gag agg gta gcc gct  
 Q V H D E L V L E A P K D R A E R V A A  
 2401/801  
 ttg gcc aag gag gtc atg gag ggg gtc tgg ccc ctg cag gtg ccc ctg gag gtg gag gtg  
 L A K E V M E G V W P L Q V P L E V E V  
 2461/821  
 ggc ctg ggg gag gac tgg ctc tcc gcc aag gag tag  
 G L G E D W L S A K E

FIG. 3  
(sheet 2)

FIG. 4  
(sheet 1)

sequence 2505 b.p. ATGGAAGGATG ... GCCAAGGGTTAG linear  
coding sequence of *T. thermophilus* DNA polymerase as submitted by D. Gelfand in WO 91/09950 PCT/US90/071

```

1/1          31/11
VTG GAG GCG ATG CTT CCG CTC TTT GAA CCC AAA GGC CCG GTC CTC CTG GTG GAC GGC CAC
4 E A H L P L F E P K G R V L L V D G H
61/21       91/31
CAC CTG GGC TAC GGC ACC TTC TTC GGC CTG AAG GGC CTC ACC ACC ACC CCG GGC GAA CCG
H L A Y R T F F A L K G L T T S R G E P
121/41     151/51
GTG CAG GCG GTC TAC GGC TTC GGC AAG AGC CTC CTC AAG GGC CTG AAG GAG GAC GGG TAC
V Q A V Y G F A K S L L K A L K E D G Y
181/61     211/71
AAG GGC GTC TTC CTG GTC TTT GAC GGC AAG GGC CCC TCC TTC CCG CAC GAG GGC TAC GAG
K A V F V V F D A K A P S F R H E A Y E
241/81     271/91
GCC TAC AAG GCG GCG AGG GGC CCG ACC CCC GAG GAC TTC CCC CCG CAG CTC GGC CTC ATC
A Y K A G R A P T P E D F P R Q L A L I
301/101    331/111
AAG GAG CTG GTG GAC CTC CTG GCG TTT ACC CCG CTC GAG GTC CCC GGC TAC GAG CCG GAC
K E L V D L L G F T R L E V P G Y E A D
361/121    391/131
GAC GTT CTC GGC ACC CTG GGC AAG AAG GCG GAA AAG GAG GCG TAC GAG GTG CCG ATC CTC
D V L A T L A K K A E K E G Y E V R I L
421/141    451/151
ACC GGC GAC CCG GAC CTC TAC CAA CTC GTC TCC GAC CCG GTC CCG GTC CTC CAC CCC GAG
T A D R D L Y Q L V S D R V A V L H P E
481/161    511/171
GGC CAC CTC ATC ACC CCG GAG TGG CTT TGG GAG AAG TAC GGC CTC AGG CCG GAG CAG TGG
G H L I T P E W L W E K Y G L R P E Q W
541/181    571/191
GTG GAC TTC CCG GGC CTC GTG GCG GAC CCC TCC GAC AAC CTC CCC GCG GTC AAG GGC ATC
V D F R A L V G D P S D N L P G V K G I
601/201    631/211
GGG GAG AAG ACC GGC CTC AAG CTC CTC AAG GAG TGG GGA AGC CTG GAA AAC CTC CTC AAG
G E K T A L K L L K E W G S L E N L L K
661/221    691/231
AAC CTG GAC CCG GTA AAG CCA GAA AAC GTC CCG GAG AAG ATC AAG GGC CAC CTG GAA GAC
N L D R V K P E N V R E K I K A H L E D
721/241    751/251
CTC AGG CTC TCC TTG GAG CTC TCC CCG GTG CCG ACC GAC CTC CCC CTG GAG GTG GAC CTC
L R L S L E L S R V R T D L P L E V D L
781/261    811/271
GGC CAG CCG CCG GAG CCC GAC CCG GAG GCG CTT AGG GGC TTC CTG GAG AGG CTG GAG TTC
A Q G R E P D R E G L R A F L E R L E F
841/281    871/291
GGC ACC CTC CTC CAC GAG TTC GGC CTC CTG GAG GGC CCC GGC CCC CTG GAG GAG GGC CCC
G S L L H E F G L L E A P A P L E E A P
901/301    931/311
TGG CCC CCG CCG GAA GCG GGC TTC GTG GGC TTC GTC CTC TCC CCG CCC GAG CCC ATG TGG
W P P P E G A F V G F V L S R P E P H W
961/321    991/331
GGG GAG CTT AAA GGC CTG GGC GGC TGC AGG GAC GGC CCG GTG CAC CCG GCA GCA GAC CCC
A E L K A L A A C R D G R V H R A A D P
1021/341   1051/351
TTG CCG GCG CTA AAG GAC CTC AAG GAG GTC CCG GGC CTC CTC GGC AAG GAC CTC GGC GTC
L A G L K D L K E V R G L L A K D L A V
1081/361   1111/371
TTG GGC TGG AGG GAG GCG CTA GAC CTC GTG CCC GGG GAC GAC CCC ATG CTC CTC GGC TAC
L A S R E G L D L V P G D D P H L L A Y
1141/381   1171/391
CTC CTG GAC CCC TCC AAC ACC ACC CCC GAG CCG GTG CCG CCG TAC GCG GCG GAG TCG
L L D P S N T T P E G V A R R Y G G E W

```

1201/401  
 ACG GAG GAC GCC GCC CAC CGG GCC CTC CTC TCG GAG AGG CTC CAT CGG AAC CTC CTT AAG  
 T E D A A H R A L L S E R L H R N L L K  
 1261/421  
 GGC CTC GAG GGG GAG GAG AAG CTC CTT TGG CTC TAC CAC GAG GTG GAA AAG CCC CTC TCC  
 R L E G E E K L L W L Y H E V E K P L S  
 1321/441  
 CGG GTC CTG GCC CAC ATG GAG GCC ACC GGG GTA CGG CTG GAC GTG GCC TAC CTT CAG GCC  
 R V L A H M E A T G V R L D V A Y L Q A  
 1381/461  
 CTT TCC CTG GAG CTT GCG GAG GAG ATC CGC CGC CTC GAG GAG GAG GTC TTC GCG TTG GCG  
 L S L E L A E E I R R L E E E V F R L A  
 1441/481  
 GGC CAC CCC TTC AAC CTC AAC TCC CGG GAC CAG CTG GAA AGG GTG CTC TTT GAC GAG CTT  
 G H P F N L N S R D Q L E R V L F D E L  
 1501/501  
 AGG CTT CCC GGC TTG GGG AAG ACG CAA AAG ACA GGC AAG CGC TCC ACC AGC GCC GCG GTG  
 R L P A L G K T Q K T G K R S T S A A V  
 1561/521  
 CTG GAG GCC CTA CGG GAG GCC CAC CCC ATC GTG GAG AAG ATC CTC CAG CAC CGG GAG CTC  
 L E A L R E A H P I V E K I L Q H R E L  
 1621/541  
 ACC AAG CTC AAG AAC ACC TAC GTG GAC CCC CTC CCA AOC CTC GTC CAC CCG AGG ACG GGC  
 T K L K N T Y V D P L P S L V H P R T G  
 1681/561  
 GGC CTC CAC ACC CGC TTC AAC CAG ACG GCC ACG GCC ACG GGG AGG CTT AGT AGC TCC GAC  
 R L H T R F N Q T A T A T G R L S S S D  
 1741/581  
 CCC AAC CTG CAG AAC ATC CCC GTC CGC ACC CCC TTG GGC CAG AGG ATC CGC CGG GCC TTC  
 P N L Q N I P V R T P L G Q R I R R A F  
 1801/601  
 GTG GCC GAG GCG GGT TGG GCG TTG GTG GCC CTG GAC TAT AGC CAG ATA GAG CTC CGC GTC  
 V A E A G W A L V A L D Y S Q I E L R V  
 1861/621  
 CTC GCC CAC CTC TCC GGG GAC GAA AAC CTG ATC AGG GTC TTC CAG GAG GCG AAG GAC ATC  
 L A H L S G D E N L I R V F Q E G K D I  
 1921/641  
 CAC ACC CAG ACC GCA AGC TGG ATG TTC GGC CTC CCC CGG GAG GCC GTG GAC CCC CTG ATG  
 H T Q T A S W M F G V P P E A V D P L M  
 1981/661  
 GGC CGG GCG GCC AAG ACG GTG AAC TTC GGC CTC CTC TAC GGC ATG TCC GCC CAT AGG CTC  
 R R A A K T V N F G V L Y G M S A H R L  
 2041/681  
 TCC CAG GAG CTT GCC ATC CCC TAC GAG GAG GCG GTG GCC TTT ATA GAG GGC TAC TTC CAA  
 S Q E L A I P Y E E A V A F I E R Y F Q  
 2101/701  
 AGC TTC CCC AAG GTG CGG GCC TGG ATA GAA AAG ACC CTG GAG GAG GGG AGG AAG CGG GGC  
 S F P K V R A W I E K T L E E G R K R G  
 2161/721  
 TAC GTG GAA ACC CTC TTC CGA AGA AGC CGC TAC CTG CCC GAC CTC AAC GCC CGG GTG AAG  
 Y V E T L F G R R R Y V P D L N A R V K  
 2221/741  
 AOC GTC AGG GAG GCC GCG GAG CGC ATG GCC TTC AAC ATG CCC GTC CAG GGC ACC GGC GGC  
 S V R E A A E R M A F N M P V Q G T A A  
 2281/761  
 GAC CTC ATG AAG CTC GCC ATG GTG AAG CTC TTC CCC CGC CTC CGG GAG ATG GGG GCC CGC  
 D L M K L A M V K L F P R L R E M G A R  
 2341/781  
 ATG CTC CTC CAG GTC CAC GAC GAG CTC CTC CTG GAG GCC CCC CAA GCG CGG GCC GAG GAG  
 H L L Q V H D E L L L E A P Q A R A E E  
 2401/801  
 GTG GCG GCT TTG GCC AAG GAG GCC ATG GAG AAG GCC TAT CCC CTC GCC GTG CCC CTG GAG  
 V A A L A K E A M E K A Y P L A V P L E  
 2461/821  
 GTG GAG GTG GGG ATG GGG GAG GAC TGG CTT TCC GCC AAG GGT TAG  
 V E V G M G E D W L S A K G

 FIG. 4  
 (sheet 2)



FIG. 5

(Sheet 1)

DNA and protein sequence of the coding region of pMR8, encoding FY4

1/1	31/11
ATG CTG GAA CGT CTG GAA TTC GGC AGC CTC	CTC CAC GAG TTC GGC CTC CTG GAG GCC CCC
M L E R L E F G S L	L H E F G L L E A P
61/21	91/31
GCC CCC CTG GAG GAG GCC CCC TGG CCC CCG	CCG GAA GGG GCC TTC GTG GGC TTC GTC CTC
A P L E E A P W P P	P E G A F V G F V L
121/41	151/51
TCC CGC CCC GAG CCC ATG TGG GCG GAG CTT	AAA GCC CTG GCC GCC TGC AGG GAC GGC CGG
S R P E P M W A E L	K A L A A C R D G R
181/61	211/71
GTG CAC CGG GCA GCA GAC CCC TTG GCG GGG	CTA AAG GAC CTC AAG GAG GTC CGG GGC CTC
V H R A A D P L A G	L K D L K E V R G L
241/81	271/91
CTC GCC AAG GAC CTC GCC GTC TTG GCC TCG	AGG GAG GGG CTA GAC CTC GTG CCC GGG GAC
L A K D L A V L A S	R E G L D L V P G D
301/101	331/111
GAC CCC ATG CTC CTC GCC TAC CTC CTG GAC	CCC TCC AAC ACC ACC CCC GAG GGG GTG GCG
D P M L L A Y L L D	P S N T T P E G V A
361/121	391/131
CGG CGC TAC GGG GGG GAG TGG ACG GAG GAC	GCC GCC CAC CGG GCC CTC CTC TCG GAG AGG
R R Y G G E W T E D	A A H R A L L S E R
421/141	451/151
CTC CAT CGG AAC CTC CTT AAG CGC CTC GAG	GGG GAG GAG AAG CTC CTT TGG CTC TAC CAC
L H R N L L K R L E	G E E K L L W L Y H
481/161	511/171
GAG GTG GAA AAG CCC CTC TCC CGG GTC CTG	GCC CAC ATG GAG GCC ACC GGG GTA CGG CTG
E V E K P L S R V L	A H M E A T G V R L
541/181	571/191
GAC GTG GCC TAC CTT CAG GCC CTT TCC CTG	GAG CTT GCG GAG GAG ATC CGC CGC CTC GAG
D V A Y L Q A L S L	E L A E E I R R L E
601/201	631/211
GAG GAG GTC TTC CGC TTG GCG GGC CAC CCC	TTC AAC CTC AAC TCC CGG GAC CAG CTG GAA
E E V F R L A G H P	F N L N S R D Q L E
661/221	691/231
AGG GTG CTC TTT GAC GAG CTT AGG CTT CCC	GCC TTG GGG AAG ACG CAA AAG ACA GGC AAG
R V L F D E L R L P	A L G K T Q K T G K
721/241	751/251
CGC TCC ACC AGC GCC GCG GTG CTG GAG GCC	CTA CGG GAG GCC CAC CCC ATC GTG GAG AAG
R S T S A A V L E A	L R E A H P I V E K
781/261	811/271
ATC CTC CAG CAC CGG GAG CTC ACC AAG CTC	AAG AAC ACC TAC GTG GAC CCC CTC CCA AGC
I L Q H R E L T K L	K N T Y V D P L P S
841/281	871/291
CTC GTC CAC CCG AGG ACG GGC GCG CTC CAC	ACC CGC TTC AAC CAG ACG GCC ACG GCC ACG
L V H P R T G R L H	T R F N Q T A T A T
901/301	931/311
GGG AGG CTT AGT AGC TCC GAC CCC AAC CTG	CAG AAC ATC CCC GTC CGC ACC CCC TTG GGC
G R L S S S D P N L	Q N I P V R T P L G
961/321	991/331
CAG AGG ATC CGC CGG GCC TTC GTG GCC GAG	GCG GGT TGG GCG TTG GTG GCC CTG GAC TAT
Q R I R R A F V A E	A G W A L V A L D Y
1021/341	1051/351

FIG 5.  
(Sheet 2)

AGC CAG ATA GAG CTC CGC GTC CTC GCC CAC CTC TCC GGG GAC GAA AAC CTG ATC AGG GTC  
 S Q I E L R V L A H L S G D E N L I R V  
 1081/361 1111/371  
 TTC CAG GAG GGG AAG GAC ATC CAC ACC CAG ACC GCA AGC TGG ATG TTC GGC GTC CCC CCG  
 F Q E G K D I H T Q T A S W M F G V P P  
 1141/381 1171/391  
 GAG GCC GTG GAC CCC CTG ATG GGC CGG GCG GCC AAG ACG GTG AAC TAC GGC GTC CTC TAC  
 E A V D P L M R R A A K T V N Y G V L Y  
 1201/401 1231/411  
 GGC ATG TCC GCC CAT AGG CTC TCC CAG GAG CTA GCC ATC CCC TAC GAA GAA GCG GTG GCC  
 G M S A H R L S Q E L A I P Y E E A V A  
 1261/421 1291/431  
 TTT ATA GAG CGC TAC TTC CAA AGC TTC CCC AAG GTG CGG GCC TGG ATA GAA AAG ACC CTG  
 F I E R Y F Q S F P K V R A W I E K T L  
 1321/441 1351/451  
 GAG GAG GGG AGG AAG CGG GGC TAC GTG GAA ACC CTC TTC GGA AGA AGG CGC TAC GTG CCC  
 E E G R K R G Y V E T L F G R R R Y V P  
 1381/461 1411/471  
 GAC CTC AAC GCC CGG GTG AAG AGC GTC AGG GAG GCC GCG GAG CGC ATG GCC TTC AAC ATG  
 D L N A R V K S V R E A A E R M A F N M  
 1441/481 1471/491  
 CCC GTC CAG GGC ACC GCC GCC GAC CTC ATG AAG CTC GCC ATG GTG AAG CTC TTC CCC CGC  
 P V Q G T A A D L M K L A M V K L F P R  
 1501/501 1531/511  
 CTC CGG GAG ATG GGG GCC CGC ATG CTC CTC CAG GTC CAC GAC GAG CTC CTC CTG GAG GCC  
 L R E M G A R M L L Q V H D E L L L E A  
 1561/521 1591/531  
 CCC CAA GCG CGG GCC GAG GAG GTG GCG GCT TTG GCC AAG GAG GCC ATG GAG AAG GCC TAT  
 P Q A R A E E V A A L A K E A M E K A Y  
 1621/541 1651/551  
 CCC CTC GCC GTG CCC CTG GAG GTG GAG GTG GGG ATG GGG GAG GAC TGG CTT TCC GCC AAG  
 P L A V P L E V E V G M G E D W L S A K  
 1681/561  
 GGT TAG  
 G \*



European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number  
EP 96 30 3880

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (In CL6)
D,A	WO-A-92 06188 (BARNES WAYNE M) * the whole document *	1-9	C12N15/54 C12N9/12 C12Q1/68
A	WO-A-91 09944 (CETUS CORP) * the whole document *	1-9	
A	WO-A-94 05797 (KISELEV VSEVOLOD ;SEVERIN EVGENII (RU); KORPELA TIMO (FI)) * the whole document *	1-9	
D,A	EUR. J. BIOCHEM. (1992), 209(1), 351-5 CODEN: EJBCEI;ISSN: 0014-2956, 1992, XP000578012 RICHTER, OLIVER MATTHIAS H. ET AL: "Cloning and sequencing of the gene for the cytoplasmic inorganic pyrophosphatase from the thermoacidophilic archaebacterium Thermoplasma acidophilum" * the whole document *	1-9	
A	WO-A-90 12111 (HARVARD COLLEGE) * the whole document *	1-9	TECHNICAL FIELDS SEARCHED (In CL6)
P,X, D	EP-A-0 655 506 (PRESIDENT AND FELLOWS OF HARVARD COLLEGE, USA) * page 6, line 15 - line 17; claims 1-52 *	1,6,9	C12N C12Q
P,X	NATURE, vol. 376, 31 August 1995, MACMILLAN JOURNALS LTD., LONDON,UK, pages 796-797, XP002089831 M.A. REEVE AND C.W. FULLER: "A novel thermostable polymerase for DNA sequencing" * the whole document *	1-9	
-/--			
The present search report has been drawn up for all claims			
Place of search		Date of completion of the search	Examiner
THE HAGUE		20 September 1996	Hornig, H
<p><b>CATEGORY OF CITED DOCUMENTS</b></p> <p>X : particularly relevant if taken alone  V : particularly relevant if combined with another document of the same category  A : technological background  O : non-written disclosure  F : intermediate document</p> <p>T : theory or principle underlying the invention  E : earlier patent document, but published on, or after the filing date  D : document cited in the application  L : document cited for other reasons</p> <p>A : number of the same patent family, corresponding document</p>			

EP 0 FORM 1801 (Rev. 01/94)



European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number  
EP 96 30 3888

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
P,X	AMERSHAM LIFE SCIENCE, EDITORIAL COMMENTS, vol. 22, no. 2, July 1995, pages 29-36, XP002009832 S.B. SAMOLS ET AL.: "Thermo Sequenase; a new thermostable DNA polymerase for DNA sequencing" * the whole document *	1-9	
P,A	PROC. NATL. ACAD. SCI. U. S. A. (1995), 92(14), 6339-43 CODEN: PNASA6;ISSN: 0027-8424, 3 July 1995, XP002009833 TABOR, STANLEY ET AL: "A single residue in DNA polymerases of the Escherichia coli DNA polymerase I family is critical for distinguishing between deoxy- and dideoxyribonucleotides" * the whole document *	1-9	
			TECHNICAL FIELDS SEARCHED (Int.Cl.6)
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 20 September 1996	Examiner Hornig, H
<p><b>CATEGORY OF CITED DOCUMENTS</b></p> <p>X: particularly relevant if taken alone Y: particularly relevant if combined with another document of the same category A: technological background O: non-written disclosure P: intermediate document</p> <p>T: theory or principle underlying the invention E: earlier patent document, but published on, or after the filing date D: document cited in the application L: document cited for other reasons A: member of the same patent family, corresponding document</p>			

EPO FORM 1501 (01/95)